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ABSTRACT 
Lactococcus lactis prolidase (Llaprol) hydrolyzes Xaa-Pro dipeptides.  Since Xaa-Pro is 
known as bitter peptides, Llaprol is potentially applicable to reduce bitterness of fermented foods.  
Llaprol shows allosteric behaviour and substrate inhibition, which are not reported in other 
prolidases.  Computer models of Llaprol based on an X-ray structure of non-allosteric 
Pyrococcus furiosus prolidase showed that a loop
 
structure (Loop
32-43
) is located at the interface 
of the protomers of this homodimeric metallodipeptidase.  This study investigated roles of four 
charged residues (Asp
36
, His
38
, Glu
39
, and Arg
40
) of Loop
32-43
 in Llaprol using a combination of 
kinetic examinations of ten mutant enzymes and their molecular models.  Deletion of the loop 
structure by 36-40 mutant resulted in a loss of activity, indicating Loop32-43 is crucial for the 
activity of Llaprol.  D36S and H38S exhibited 96.2 % and 10.3 % activity of WT, whereas little 
activities (less than 1.0 % of WT activity) were observed for mutants E39S, D36S/E39S, R40S, 
R40E, R40K and H38S/R40S.  These results implied that Glu
39
 and/or Arg
40
 play critical role(s) 
in maintaining the catalytic activity of Llaprol.  These observations suggested that the loop 
structure is flexible and this attribute, relying on charge-charge interactions contributed by Arg
40
, 
Glu
39
 and Lys
108
, is important in maintaining the activity of Llaprol.  When the loop takes a 
conformation close to the active site (closed state), Asp
36
 and His
38
 at the tip of the loop can be 
involved in the catalytic reaction of Llaprol.  The two active mutant prolidases (D36S and H38S) 
resulted in modifications of the unique characteristics; the allosteric behaviour was not observed 
for D36S, and H38S Llaprol showed no substrate inhibition.  D36E/R293K, maintaining the 
negative charge of position 36 and positive charge of position 293, still possessed the allosteric 
behaviour, whereas the loss of the charges at these positions (D36S of this study and R293S of a 
previous study (Zhang et al., 2009 BBA-Proteins Proteom 1794, 968-975) eliminated the 
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allosteric behaviour.  These results indicated the charge-charge attraction between Asp
36
 and 
Arg
293
 is important for the allostery of Llaprol.  In the presence of either zinc or manganese 
divalent cations as the metal catalytic centre, D36S and H38S enzymes also showed different 
substrate preferences from WT Llaprol, implying the influence of Asp
36
 and His
38
 on the 
substrate binding.  D36S and H38S also showed higher activities at pH 5.0 to 6.0, in which range 
WT Llaprol steeply decreased its activity, indicating Asp
36
 and His
38
 are involved in the active 
centre and influence the microenvironment of catalytic His
296
.  The above observations are 
attributed to modifications of their local structure in the active centre since the temperature 
dependency and thermal denaturing temperature indicated little effects on the overall structure of 
the Llaprol mutants. 
From these results, we concluded that the unique behaviours of Llaprol are correlated to 
Loop
32-43
 and Asp
36
 and His
38
 on it. When Loop
32-43
 takes a closed conformation, Asp
36
 interacts 
with Arg
293
 via charge-charge attraction to form an allosteric subsite.  The saturation of the 
allosteric site with substrates further allowed the communications of His
38
 with S1 site residues to 
complete the active site.  When the substrate concentration becomes higher than it is required to 
saturated productive S1‟ site, His
38
, Phe
190
 and Arg
293
 would resemble the residue arrangement of 
S1‟ site residues (His
292
, Tyr
329
, and Arg
337
) and bind to the proline residue of substrates.  This 
non-productive binding would prevent the conformational change of Loop
32-43
, which further 
results in the substrate inhibition.  For further confirmation of this mechanism, crystallographic 
studies will be conducted.  In this thesis, we have indentified the conditions to produce crystals 
of Llaprol proteins.  
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1 INTRODUCTION 
Fermented foods attract attention from consumers in terms of their health benefits.  One of 
the major expenses in making fermented foods, such as cheese, is the costs to age the fermented 
foods to allow development of their distinctive flavours (Fukushima, 1979; Roberts and Vickers, 
1994).  The ageing processes generally take months to years to complete.  This long duration is 
required to diminish off-flavours which are prominent defects in the early stage of ageing.  
Efficient reduction of off-flavours would shorten the ageing process of the food fermentation 
while keeping higher acceptability by consumers.  Proline-containing peptides, including Xaa-
Pro, largely account for the bitterness of fermented foods, and these peptides are less accessible 
to general peptidases due to the presence of an imino ring structure.  Since Xaa-Pro is an ultimate 
product of proteolysis by general peptidases, Xaa-Pro dipeptidase (prolidase), which specifically 
hydrolyzes Xaa-Pro, would be useful in debittering processes and shortening the ageing time for 
the fermented food industry. 
Prolidase is also an essential metabolic enzyme in human bodies.  Prolidase deficiency (PD) 
caused by a malfunction of prolidase results in clinical symptoms, such as severe skin lesions, 
facial abnormalities, chronic joint dislocations, bacterial infections, and mental retardation 
(Powell et al., 1974).  An enzyme replacement therapy using an activated prolidase is considered 
to treat PD (Colonna et al., 2008).  Furthermore, prolidase is considered as a potential tool to 
detoxify nerve gas chemicals through their hydrolysis (Ditargiani et al., 2010).   
Lactic acid bacteria are well-known as a GRAS (generally recognized as safe) 
microorganism.  Prolidase produced from Lactococcus lactis is ideal for food and medical 
applications.  Therefore, a comprehensive understanding of Lactococcus lactis prolidase (Llaprol) 
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in terms of its structure and function relationships would provide valuable information to adapt 
Llaprol to such applications.  
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2 LITERATURE SURVEY 
2.1 Biotechnological Applications of Prolidase 
2.1.1 Fermented Food Industries 
Fermented foods are established and widely accepted as a category of foods.  They include 
many traditional foods, such as cheese (fermented casein), summer sausage, pickled vegetables, 
miso (salted and fermented soybean paste), soy sauce, fish sauce, natto (fermented soybeans), 
and katsuobushi (dried fish meat) (Maehashi and Huang, 2009).  During processes of the food 
fermentation, a wide range of peptides are generated through protein hydrolysis and contributes 
to flavours and off-flavours of the fermented foods.  Off-flavours, such as bitterness arisen from 
bitter peptides, are not preferred in terms of the customer acceptance.  To attain customers‟ 
acceptance, flavour masking or bitter compound degradation is required.  Prolidase would be 
used as a debittering agent in the preparation of fermented foods through the degradation of 
bitter peptides into free amino acids, which generally have little flavours.   
2.1.1.1 Bitter Peptides in Cheese   
Cheese is a traditional dairy food in Western countries.  A cheese making process mainly 
involves three steps: curding, curd processing, and ageing.  In the curding step, milk is 
coagulated into solid curd by adding bacteria culture and coagulating enzymes.  The curd is 
drained, salted, and moulded in curd processing which usually produces a salty yet bland cheese 
(Walter et al., 1969).  In the ageing process (also called ripening), metabolic activities of starter 
bacteria and their enzymes transform texture and flavours of cheese.  The transformation relies 
on the breakdown of casein proteins and milk fats in unripened cheese into a complex mixture of 
amino acids, peptides, and fatty acids, which contribute to the distinctive flavours of cheese.  
  
4 
Ageing processes can take from a few months to several years and the length of ageing directly 
affects the degree of ripening. 
The degree of ripening can result in different intensity of bitterness.  By using Lactococcus 
lactis ssp. lactis S3 as a starter bacterium, Cheddar cheese is slightly bitter at two, four and six 
months of ripening, even bitter after two years (Broadbent et al., 1998).  When the bitterness is 
pronounced, it can negatively influencing the acceptance and marketability of cheese.  It was 
reported that the bitter flavour in cheese is due to the degradation of casein proteins to peptides 
(Bumberger and Belitz, 1993).  Past investigations have confirmed that the proteolytic systems in 
starter bacteria play a crucial role in the flavour formation, including bitterness (Thomas and 
Pritchard, 1987).  The proteinases slowly degrade polypeptides, such as αs1-casein to 
oligopeptides and free amino acids (Visser et al., 1983).  Some of these oligopeptides taste bitter.  
A study on enzymatic hydrolysis of casein showed that resultant oligopeptides from residue 
position 49 to 97, comprising a large variety of proline-containing peptides, are the contributors 
to the bitter flavour (Bumberger and Belitz, 1993).  The result of this experiment was further 
validated by the analysis of isolated peptides from Cheddar cheese (Lee and Warthesen, 1996), 
which showed that proline-containing peptides are key players in the bitterness of cheeses. 
2.1.1.2 Bitter Peptides in Other Fermented Food Makings 
Sufu (Chinese soybean cheese) making includes a preparation of the tofu from soybean, 
solid-state fermentation with fungi (e.g., Actinomucor elegans), salting and ripening.  Hydrolysis 
of soybean protein in tofu into peptides and amino acids occurs during the ripening stages, which 
normally take three to six months (Han et al., 2004).  This hydrolysis develops distinctive 
flavours of sufu.  The soybean protein is composed of four main proteins,  α, β, γ-conglycinin 
and 11S glycinin (Kim et al., 2003).  Kim et al. (2008) showed that 21 bitter peptides are found 
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in hydrolysate of Soybean 11S glycinin.  Nine of the 21 peptides are revealed as proline-
containing peptides (such as Arg-Pro, Asn-Ala-Glu-Lys-Pro-Asp, Gln-Ala-Leu-Pro-Glu, Gly-
Met-Ile-Tyr-Pro-Gly, Ala-Leu-Glu-Pro-Asp-His-Arg, Ile-Tyr-Pro-Gly, and Ile-Tyr-Pro-Gly-Cys-
Pro-Ser-Asp). 
Fish sauce is a type of food flavouring made through fermentation of fish.  Fish sauce that 
has been only briefly fermented has an apparent fishy taste, whereas extended fermentation gives 
products nuttier, cheesier and bitter flavours instead.  Fish sauce is known for its high contents of 
oligopeptides formed as a consequence of microbial fermentation.  Park et al. (2002) observed 
that a proline residue exists at the C-terminus of six dipeptides or in the middle of five tripeptides 
among 17 peptides isolated from fish sauce using HPLC.  These proline-containing peptides are 
bitter tastes based on a sensory evaluation.  It was reported that the addition of 
dipeptidylpeptidases to a fish sauce accelerates the fermentation and yields products with 
desirable tastes (Raksakulthai and Haard, 2003). 
2.1.1.3 Proline-Containing Peptides 
Above studies on fermented foods found that the undesirable bitter taste is caused by the 
formation of bitter peptides during production processes.  When the concentration of bitter 
peptides exceeds taste threshold values (TV), a bitterness defect is detected.  As mentioned in 
section 2.1.1.1 and 2.1.1.2, proline-containing peptides dominate bitterness in fermented 
products.  The molecular mechanism how proline-containing peptides show bitterness attracts 
research attentions but it is still under debate (Kiw et al., 2008). 
Ney (1971) proposed that the bitterness of a peptide is correlated to its Q-value (Q=ΣΔf/n), 
which is an average of the hydrophobicity of the side chain of the constituent amino acid 
residues (Δf reflects the hydrophobicity of an individual amino acid residue, and n is the number 
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of amino acid residues).  According to the Q rule, peptides with molecular weight (MW) less 
than 6,000 Da and a Q-value higher than 1,400 cal/mol are bitter peptides.  However, the 
accuracy of the Q-rule is limited because other parameters such as primary and seconday 
structures of peptides account for the bitter tastes (Asao et al., 1987).  For instance proline-
containing bitter peptides isolated from Guoda cheese, do not obey this Q-rule (Toelstede and 
Hofmann, 2008). 
Otagiri et al. (1985) have reported the Arg-Pro is 1.25-times bitter than caffeine.  Threshold 
values (Table 2.1-1) of Arg-Pro and its similar peptides are determined through structure and 
sensory analyses by Ishibashi et al. (1988).  This article discussed the significant role of proline 
in the bitterness of peptides, and they proposed a rule to determine the bitterness of peptide using 
structural factors.  Bitterness of peptides is determined by two structural factors: binding unit 
(BU) and stimulating unit (SU).  Bitterness is exhibited when both units exist in a molecule and 
they simultaneously bind to a bitter taste receptor.  Taking Arg-Pro as an example, the imino ring 
of proline residue acts as BU and the adjacent arginine residue plays the role of SU.  They 
argued that these two units must be adjacent to each other in three-dimensional structure of 
peptides.  As shown in Figure 2.1-1, the steric distance between the two units and the diameter of 
bitter taste receptor are estimated as 4.1 Å (Ishibashi et al., 1988) and 15 Å (Tamura et al.,1990), 
respectively.   
This group further investigated the role of proline residues in the bitter taste of peptides.  
They showed that another significant role of the proline residue in bitter peptides is the 
conformational alteration of the proline-containing peptide molecules.  R-groups of amino acids 
can occur in either cis- or trans-configuration and the bulkiness of R-groups of most amino acids 
normally prefers to take the trans-configuration (99.95% probability).  However, proline  
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Table 2.1-1  Threshold values of peptides examined in studies of Ishibashi et al (1998)  
 
Peptides Threshold value (TV) 
Arg-Pro 0.8 mM 
Arg-Arg 8.0 mM 
Arg-Gly 10.0 mM 
Pro-Arg 3.0 mM 
Arg-Gly-Pro 13.0 mM 
Arg-Pro-Gly 0.8 mM 
Gly-Arg-Pro 0.8 mM 
 
 
 
 
Figure 2.1-1  A model for binding of bitter peptides to bitter taste receptors. 
A bitter peptide is shown in red and a bitter-taste receptor is shown in blue.  The distance 
between binding unit (BU) and stimulating unit (SU) in peptides should be around 4.1 Å.  The 
pocket size formed in the bitterness receptor region is approximately 15 Å. (adapted from 
Ishibashi et al. (1988) and Tamura et al. (1990)) 
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frequently flips between cis- and trans-configurations than other amino acids, and the probability 
of cis-configuration of proline residues is 5–6 %, which is about 100-times higher than other 
amino acids (Buxbaum, 2005).  This feature of proline allows the conformational isomerization 
of proline-containing peptides, which may have an influence on the generation of bitterness of 
these peptides. 
2.1.1.4 Lactococcus lactis Prolidase in Fermented Food Processing 
Milk casein and soybean protein are proline-rich proteins, and proline-containing peptides 
generated from the hydrolysis of these proteins are reported as key contributors to the bitterness 
of fermented products (Ishibashi et al., 1988).  Attempts have been made to remove or mask the 
bitterness in fermented foods.  It is logical that the use of peptidases to hydrolyze bitter peptides 
into free amino acids, which normally have less flavour, can reduce the bitterness in fermented 
foods.  However, proline-containing peptides are inaccessible to common exo- and 
endopeptidases such as general peptidases, di- and tripeptidases (Mcdonald et al., 1969), due to 
the existence of the imino structure of proline.  Thus proline specific peptidases, including 
proline aminopeptidase P, Xaa-Prolyl dipeptidyl peptidases, proline iminopeptidase, postproline 
endopeptidase, prolinase, and prolidase are required to hydrolyze proline-containing peptides.  
Among these enzymes, prolidase and prolinase are two of the most important enzymes because 
they degrade the ultimate products of general proteolysis, Xaa-Pro and Pro-Xaa, into free amino 
acids. 
Lactococcus lactis is a natural microorganism used as a starter bacterium for making many 
types of cheeses.  Prolidase from Lactococcus lactis can be an excellent mediator to remove 
bitterness arisen from proline peptides in cheese-making.  Thus the structure-function 
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relationship study of Lactococcus lactis prolidase (Llaprol) shall provide valuable information to 
further modify Llaprol for practical applications.   
2.1.2 Prolidase in Human Health 
Prolidase deficiency (PD) is a rare recessive disorder caused by mutations in the prolidase 
gene and characterized by severe skin lesions, facial abnormalities, chronic joint dislocations, 
bacterial infections, and mental retardation (Endo et al., 1982).  The pathogen of PD is still 
unclear even though it is proposed to relate to the collagen recycling.  Collagen protein accounts 
for 70 % of skin proteins, which contains a large amount of proline residues.  Prolidase plays an 
important role in the breakdown of collagen and intracellular proteins especially in the final stage 
when peptides and dipeptides contain a high level of proline residue (Palka and Phang, 1997).  
Due to a malfunction of prolidase, the patients are not able to hydrolyze the proline containing 
peptides, resulting in the accumulation of proline-containing peptides, which causes the 
symptom of PD in patients. 
To treat PD, enzyme replacement therapy has been considered.  Ogata et al. (1981) and 
Endo et al. (1982) attempted transfusion of PD patients with normal matched erythrocytes.  Due 
to the inactive form of prolidase in erythrocytes, no effect on clinical symptoms of 
iminodipeptiduria was observed in these two studies.  Hechetman et al. (1988) activated the 
prolidase in erythrocytes with MnCl2 before transfusion, and positive results were obtained, 
which provided a fresh approach to enzyme replacement therapy in PD.  However, further 
clinical trials are required to evaluate this manganese–activated erythrocyte system to be applied 
in PD treatment.  Colonna et al. (2008) suggested an innovative therapeutic approach for PD 
with employing prolidase-loaded chitosan nanoparticles and they successfully introduced and 
restore the active form prolidase into PD fibroblasts for 8 days. 
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Lactococcus lactis prolidase can be an alternative source to be applied in treating PD, since 
Lactic acid bacteria are recognized as GRAS (generally recognized as safe) microorganisms.  
The comprehensive understanding of Llaprol in terms of structure and function would facilitate 
its applications in this area. 
2.1.3 Prolidase in Nerve Gas Degradation 
Nerve gases are a class of extremely-poisonous chemical compounds to human beings and 
they can disrupt the transduction of nerve signals to organs when these chemicals are absorbed.  
Prolidase has been considered as an potential target for treating nerve gas contaminations, 
because prolidases showed activities on P-F and P-O bonds found in organophosphorus 
compounds, including the nerve gas chemicals (Vyas et al., 2010).  To improve the functionality 
of Llaprol in degradations of nerve gases, protein engineering works of Llaprol would be 
necessary.  Hence, it is significant for this purpose to elucidate the molecular mechanism of 
Llaprol.  
2.2 General Characterizations of Prolidase 
2.2.1 Catalytic Mechanism of Prolidase 
Prolidase (E.C. 3.4.13.9) is a dipeptidase, which specifically hydrolyzes dipeptides with 
prolines or hydroxyprolines at their C-terminal, as shown in Figure 2.2-1. 
H3N CH C
R
O
N
C O
O
H2O
Prolidase
H3N CH C
R
O
O
H2N
C O
O
+
Xaa ProlineXaa-Proline
(Xaa represents any amino acid)
 
Figure 2.2-1  Chemical reactions catalyzed by prolidase. 
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Prolidase belongs to a group of enzymes called metallopeptidases, enzymes that require one 
or two metal cations per active site for their full activities.  Through comparison and analyses of 
metallopeptidases in terms of structure-function relationships, prolidase is classified into a 
subclass of metallopeptidase that contains a dinuclear active-site metal cluster.  Other members 
of this subclass that have been studied at a structural level, include Escherichia coli methionine 
aminopeptidase (eMetAP) (Roderick and Matthews, 1993), Aeromonas proteolytica 
aminopeptidase (Chevrier et al., 1994), bovine leucine aminopeptidase (Strater and Lipscomb, 
1995), Escherichia coli proline aminopeptidase (Wilce et al., 1998), human methionine 
aminopeptidase-2 (Liu et al., 1998), Pyrococcus furiosus methionine aminopeptidase-1 (Tahirov 
et al., 1998), Streptomyces griseus aminopeptidase (Gilboa et al., 2001), and Pseudomonas sp. 
carboxypeptidase G2 (Rowsell et al., 1997).  These enzymes share high homology at the amino 
acid level and have a dinuclear metal centre bridged by a water molecule or a hydroxide ion.  
The metal cluster can coordinate with a bound substrate, activate a nucleophile for catalysis, and 
presumably stabilize the transition state (Lowther and Matthews, 2002). 
The high similarity in three-dimensional structures among prolidase, methionine 
aminopeptidase (MAP), amino peptidase P (APP) and creatinase (Coll et al., 1990) has these 
enzymes further cluster into a smaller subclass of metalloenzymes known as “pita-bread 
enzymes”.  Although each of these enzymes have different substrate specificities, they share 
common metal binding residues which are two aspartate, two glutamate and one histidine 
residues as shown in Figure 2.2-2, suggesting that they can have a conserved catalysis 
mechanism (Bazan et al., 1994). 
The proposed catalytic mechanistic scheme for the “pita-bread” enzymes is presented in 
Figure 2.2-3 with eMetAP as the model.  The carbonyl and amine groups of the peptide bond in  
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Figure 2.2-2  Schematic diagram of the conserved metal centre possessed by “pita-bread” 
enzymes. 
The two metal ions are shown in gray and labelled as M1 and M2.  A water molecule bridging 
two metal ions is coloured green.  Five coordinated amino acid residues are shown as labelled. 
Existing interactions are shown in bold. 
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Figure 2.2-3  Schematic view of a proposed catalytic mechanism of a “pita-bread” enzyme, 
eMetAP. 
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Substrate-peptide is shown in blue. The changes during catalysis are shown in red and orange.  
Intermediate I: Deprotonated Glu
204
 activates a metal-bound water molecule by accepting a 
proton; Intermediate II: Resultant metal-bound hydroxyl group attacks the carbonyl carbon of the 
target peptide bond.  Intermediate III: M1 and His
178
 stabilize the tetrahedral intermediate; When 
the electron bounces back to form the C=O double bond, the peptide bond breaks and Glu
204
 
donates a proton to amine of the leaving group. Intermediate IV: Products are generated and 
Glu
204
 becomes its original state to perform the next reaction. 
 
  
15 
 
substrate are stabilized by M1 (metal 1), His
178
 and His
79
.  Deprotonated Glu
204
 facilitates the 
activation of the metal-bound water molecule to become a nucleophilic hydroxide ion 
(Intermediate I).  The activated metal-bound hydroxide ion attacks the carbonyl carbon of 
peptide bond and an electron of C=O is pushed up to carbonyl oxygen (Intermediate II).  When 
the electron bounces back to re-form C=O, the peptide bond (N-C) is cleaved.  Products are 
generated when Glu
204
 donates a proton to the amine of the cleaved peptide bond (Intermediate 
III).  Two interactions to M1 and one to His
178
 stabilize the tetrahedral intermediate III during 
this stage.  The resulting product complex (IV) maintains interactions with M1 and His
178
 
(Lowther and Matthews, 2000). 
In the case of prolidase, the detailed catalytic reaction is not clear yet due to a lack of 
structural information in ligand-bound forms.  However, because of highly conserved active site 
residues of “pita-bread” enzymes, prolidase shall share similar catalytic mechanism to other 
members of “pita-bread”enzymes.  When the P1 (Xaa) and P1‟ residues (Pro) are docked in S1 
and S1‟ substrate binding sites, respectively, the metal bound water or hydroxyl ion (shown in 
Figure 2.2-3) can attack the peptide bond of Xaa-Pro.  In this process, His
296
 in Llaprol (Hu and 
Tanaka, 2009) or His
284
 in Pfprol (Maher et al, 2004) is involved as a proton receptor in the 
catalytic reaction.  Details of the mechanism of prolidase will be further introduced in section 2.4.   
2.2.2 Substrate Specificity 
Prolidase is found in a wide variety of prokaryotes and eukaryotes.  Although physiological 
functions of prolidase are not clear, this enzyme may play an important role in the recycle of 
proline.  Prolidases are characterized and purified from porcine (Davis and Smith, 1957; Manao 
et al., 1972; Sjostrom et al., 1973), bovine (Yoshimoto et al., 1983), Streptococcus cremoris 
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(Kaminogawa et al., 1984), human (Myara et al., 1994), Xanthomonas maltophilia (Suga et al., 
1995), Aureobacterium esteraromaticum (Fujii et al., 1996), Lactobacillus casei (Fernandez-
Espla et al., 1997), Lactobacillus delbrueckii (Morel et al., 1999; Rantanen and Palva, 1997), and 
Suberites domuncula (Wiens et al., 1999).  Recombinant forms of prolidase expressed in 
Escherichia coli (E. coli) are obtained from Lactobacillus delbrueckii (Stucky et al., 1995), 
Pyrococcus furiosus (Ghosh et al., 1998), and Lactococcus lactis (Yang and Tanaka, 2008).  
Human prolidase is expressed in Chinese hamster ovary (CHO) cells and Escherichia coli (Lupi 
et al., 2006).  Substrate preferences of some prolidases were reported.  Prolidases are able to 
hydrolyze Xaa-Pro dipeptides but they have a preferential activity on Xaa-Pro dipeptides that 
have hydrophobic amino acid residue at the N-terminal.  Lactobacillus delbrueckii prolidase is 
able to hydrolyze Ala-Pro, Ile-Pro, Leu-Pro, Val-Pro, His-Pro, Phe-Pro, Tyr-Pro, and Met-Pro, 
but it shows no activity to Gly-Pro and Pro-Pro (Morel et al., 1999).  Prolidase from 
Lactobacillus casei subsp. casei IFPL 731 can hydrolyze Leu-Pro, Ile-Pro, Phe-Pro, Ala-Pro, 
Val-Pro, Ala-Ala and Ala-Phe (Fernandez-Espla et al., 1997).  Both native and recombinant form 
of Pyrococcus furiosus prolidase (Pfprol) show activities on Xaa-Pro, such as Met-Pro, Leu-Pro, 
Val-Pro, Phe-Pro, Ala-Pro, and Lys-Pro, except Gly-Pro (Ghosh et al., 1998).  Park et al. (2004) 
observed Escherichia coli pepQ prolidase shows activity on proline dipeptides with polar and 
nonpolar amino acid residues at the N-terminus, and they also reported pepQ prolidase can also 
hydrolyze nerve gas chemicals (phosphate esters such as soman) in much lower turnover 
numbers than for the dipeptides.  Lactococcus lactis prolidase (Llaprol) prefers Leu-Pro, Val-Pro, 
and Phe-Pro as its substrates and has considerable activities to Lys-Pro and Arg-Pro but activity 
toward Gly-Pro, Pro-Pro, Glu-Pro, Asp-Pro and tripeptides are not observed (Yang and Tanaka, 
2008).   
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2.2.3 Metal Ion Selectivity 
Llaprol can be activated with divalent Zn
2+
 and Mn
2+
 but not by other metal ions (Yang and 
Tanaka, 2008).  Pfprol has natural metal activator Co
2+
, which can be substituted by Mn
2+
 but not 
by Mg
2+
, Ca
2+
, Fe
2+
, Zn
2+
, Cu
2+
, or Ni
2+
 (Maher et al., 2004).  Meanwhile, chelating amino acid 
residues are conserved among pita-bread enzymes, including prolidases.  It raises a question why 
the natural selection of metal ions to activate these two prolidases is different, despite the 
conserved metal ion binding residues.    
Metal ions of metalloenzymes participate in catalysis either by acting as Lewis acid catalyst 
or by altering their oxidation states (Suh, 1992).  The metal ions discussed in this thesis act as 
Lewis acid catalyst.  Several parameters of ion properties (Table 2.2-1) should be taken into 
consideration on the specificity and selectivity of metal ions in enzyme systems.  As 
demonstrated in Table 2.2-1, divalent Zn
2+
, Mn
2+
 and Co
2+
 share very similar properties in term 
of ionic radius, coordination numbers, geometries and ionization potential (Ip).  This implies the 
reason why these metal ions are observed in the catalytic centres of prolidases.  However, it is 
still unclear whether the metal ions used in vivo are inherent to the individual enzymes or are 
determined by surrounding environment of ions within the organism. 
2.3 Unique Properties of Llaprol 
Yang and Tanaka (2008) observed Llaprol possesses unique properties, allosteric behaviour 
and substrate inhibition, as shown in Figure 2.3-1, which are not reported in other prolidases.  
These properties may limit further applications of Llaprol in industrial and medical practices.  To 
manipulate these behaviours toward target applications via protein engineering, it is necessary to 
understand the underlying mechanisms of these behaviours at an atomic level. 
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Table 2.2-1  Relevant properties of metal ions discussed in the thesis. 
 
Metal Common 
oxidation 
states 
Electronic 
configuration 
Ionic 
radius 
Common 
coordination 
numbers 
Common 
coordination 
geometries 
Hardness Preferred 
donor 
Redox Ip 
(eV) 
Zn +2 [Ar]3d
10
 0.74 4 Tetrahedral Borderline N, S, O No 17.96 
    5 Square 
pyramidal/ 
Trigonal 
bipyramidal 
    
    6 Octahedral     
Mn +2 [Ar]3d
5
 0.83 4 Tetrahedral Borderline N, S, O Yes 15.64 
    5 Trigonal 
bipyramidal 
    
    6 Octahedral     
 +3 [Ar]3d
4
 0.65 5 Square 
pyramidal/ 
Trigonal 
bipyramidal 
Hard O  33.66 
    6 Octahedral     
Co +2 [Ar]3d
7
 0.75 4 Tetrahedral Borderline N, S, O Yes 17.06 
    5 Square 
pyramidal/ 
Trigonal 
bipyramidal 
    
    6 Octahedral     
 +3 [Ar]3d
6
 0.61 6 Octahedral Hard N, O Yes 33.5 
 
Note: Ionic radii all refer to six-coordinated, high-spin (when low spin is possible) ions as tabulated in 
(Shannon, 1976). Coordination numbers and geometries are taken from (Holm et al., 1996). Other properties are 
taken from (Silva and Williams, 2001). IP is the ionization potential of M to M
n+
, and is the same as the electron 
affinity for the reverse reaction from M
n+
 to M, and is taken as a measure of the Lewis acid strength of the M
n+ 
ion. 
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2.3.1 Allosteric Behaviour 
Allostery of enzyme is a behaviour whereby enzyme activity is suppressed at low substrate 
concentrations.  Kinetically, the [S]- plot of an allosteric enzyme shows a sigmoidal curve as 
shown in Figure 2.3-1, rather than a hyperbolic curve.  Hill constant (h) is used to determine 
whether an enzyme is allosteric or not.  The value of Hill constant defines the cooperativity of 
ligand binding as follows.  If h=1, then this enzyme does not have allosteric behaviour, in which 
case the affinity of the enzyme for its substrate is not dependant on the binding of other ligand 
molecules.  If h>1, then this enzyme has allosteric behaviour and shows a positively-cooperative 
reaction, in which case the affinity of enzyme for its substrate increases once a ligand molecule 
binds to the enzyme.  In allosteric regulation, the binding of ligands at one substrate subsite 
(effector site) induces a conformational change of the active site, thus activate the enzyme. 
 
 
 
 
 
Figure 2.3-1  [S]-v plot of wild type Lactococcus lactis prolidase  
The region coloured in red represents the allosteric behaviour that the velocity of the enzyme is 
suppressed at low substrate concentrations; the region coloured in light blue represents the 
substrate inhibition where the velocity of the enzyme is decreased at high substrate 
concentrations (reproduced from Yang and Tanaka, 2008). 
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Despite the importance of allosteric regulation in metabolism and gene regulation (Monod 
et al., 1963), the understanding of the structural and energetic basis of allostery has been elusive.  
For the past 40 years, allostery has been generally explained through either of two classic models: 
Monod-Wyman-Changeux (MWC) concerted model (also known as population shift model) 
(Monod et al., 1965) and Koshland-Nemethy-Filmer (KNF) sequential model, i.e., induced fit 
model (Koshland et al., 1966).  In MWC model, the allosteric protein is usually composed of at 
least two subunits and exists in two conformational states, tense (T) and relaxed (R), and the 
population ratio of these two states shifts upon ligand bindings.  In other words, when allosteric 
proteins bind to ligands (effectors), a greater population of the proteins shift from the T to R state 
and allow substrates bind for catalysis.  In contrast to the MWC model, the assumptions of the 
KNF model include that the protein exists in one conformation solely prior to binding of the 
allosteric effector; upon binding, the ligand induces a conformational change in the subunit to 
which it is bound.  This change may be transmitted to neighbouring vacant subunits at subunit 
interfaces.  For example, if one protein is composed of 100 molecules, in MWC model, before 
substrate binding, there are 50 molecules in each R and T conformation states, and they are in 
equilibrium.  Upon binding to an effector, the equilibrium is broken and a new balance will be 
achieved under the new situation that more molecules stay in R state.  After catalysis, the 
enzyme will recover the previous equilibrium.  In contrast, in the KNF model, before binding of 
effectors, all the 100 molecules are in the T state.  Upon binding to an effector, all the molecules 
assume the R conformational states. 
Due to the fast rate of conformational changes in proteins, experiments which discriminate 
between the induced-fit model and the population-shift model are hard to establish.  Volkman et 
al. (2001) provided a direct experiment evidence for the population-shift mechanism (MWC 
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model) in a phophorylation regulated signalling protein via NMR relaxation experiments.  In 
addition, this study also suggested that the population of active conformers in nitrogen regulatory 
protein C (NtrC
r
) is formed by microsecond time-scale motions.   
Mechanisms of many allosteric enzymes were widely studied using high-resolution 
structural analyses (such as X-ray crystallography) of their various liganded forms.  
Phosphodiesterase 2A (PDE 2A) is a homodimeric allosteric enzyme as shown in Figure 2.3-2-A 
and it is an example of the allosteric activation adapting induced fit model.  PDE 2A cycles 
between open (R state) and closed conformations (T state), and H-loop is favoured to occlude the 
substrate binding site to closed conformation (T state).  When the effector-cGMP is present in 
the enzyme solution, it binds to GAF-B domain, particularly 4, 2 and 3, of PDE 2A (Figure 
2.3-2-B).  The binding of cGMP to the GAF-B domain leads to the reorientation of a helix (LH2), 
which is the linker between the GAF-B and catalytic domains.  In turn, this rearrangement 
disrupts the dimmer interface and the H loop is free to swing out to expose the substrate-binding 
site (Figure 2.3-2-C, D).  Functionally, this is observed as an enzyme activation of PDE 2A 
(Pandit et al., 2009). 
The above-mentioned theories are constructed on structural changes to activate the 
allosteric enzymes.  More recent evidences showed that allostery can be mediated solely by 
protein thermal motions, without the involvement of evident structural changes.  Popovych et al. 
(2006) and Tzeng and Kalodimos (2009) provided direct experiments to support this theory.  
Catabolite activator protein (CAP) is an allosteric protein and is allosterically mediated by cAMP 
for DNA binding.  cAMP switches CAP from „off‟ state (inactive) to „on‟ state (active).  The 
binding of cAMP to a mutant CAP-S62F fails to increase the active conformation yet  
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Figure 2.3-2  Schematic view of the structure of Phosphodiesterase 2A. 
Panel A: An overall structure of human PDE 2A (residue 215 to 900).  Two molecules, A and B 
are shown in a noncrystallographic 2-fold axis of symmetry, which is shown as a black dashed 
line.  The dimer interface extends over the surface of the entire molecule.  Molecule B is shown 
in surface representation and molecule A is shown in a ribbons representation, with the ribbons 
coloured by crystallographic B-factor, blue being low and red being high.  Three domains 
(regulatory GAF-A and GAF-B and catalytic domains) are labelled, as well as the linker helices 
LH1 and LH2 that connect them.  The effector binding pocket is shown in red frame and the two 
catalytic sites occluding each other in the vicinity of the Zn
2+
 and Mg
2+
 ions (shown as gray and 
green spheres) are located in the orange frame.  Panel B: Comparison between the Apo GAF-B 
domain of human PDE 2A (green) and the cGMP-bound GAF-B domain of mouse PDE 2A 
(PDB code: 1MCO. grey).  The orientations of 1 and 5 in Apo form (human) have significant 
differences from those of effector bound form (mouse).  The two helices that define the N and C 
termini of this domain are rotated by nearly 180º and 30º, respectively, between human and 
mouse PDE 2A.  Panel C: Structure of the unliganded catalytic domain that shows the H-loop 
folded into the catalytic site and displacing the Mg
2+
 ion. The Zn
2+ 
ion is shown as a gray sphere.  
Panel D: Structure of the catalytic domain co-crystallized with 3-isobutyl-1-methylxanthine 
(IBMX), showing the H-loop swung out.  Zn
2+
 and Mg
2+
 ions are shown as gray and green 
spheres, respectively.  The pictures are adapted with modifications from Pandit et al. (2009) 
D 
A B 
C 
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strongly activates the protein for DNA binding.  By comparing the WT CAP and CAP-S62F 
mutant, they found that the allosteric activation is solely driven by changes in protein motions, 
which is dominated by conformational entropy.  cAMP is able to bind CAP in an active 
conformation that DNA binding domain (DBD) structurally poises to interact with DNA (Figure 
2.3-3-A), whereas cAMP binding to CAP-S62F stabilizes only small populations of active 
conformations (2 % of the whole populations; Figure 2.3-3-B), failing to elicit the active 
conformation.  However, DNAs can bind to these marginally active DBDs in CAP-S62F-cAMP, 
and shift inactive conformations into active ones, which are solely driven by the conformational 
entropy (Tzeng and Kalodimos, 2009). 
Allosteric proteins control fundamental biological processes, and malfunction of allosteric 
proteins can cause metabolic and genetic diseases.  However, the biochemical process occurred 
during allosteric behaviour is still not well understood.  Since the allosteric behaviour of 
industrial enzymes can be interpreted as low efficiency, its modification may be required to quest 
high efficiency.  Understanding the molecular mechanism of allosteric behaviour is significant 
for guiding the modifications of allosteric enzymes.   
2.4 Three-Dimensional Structures of Prolidase 
To date, eight three-dimensional structures of prolidases are deposited in the Protein Data 
Bank (PDB).  Three of them are from Pyrococcus horikoshii (PDB: 1WY2, 1WN1, 2HOW), two 
of them are from human (PDB: 2IW2, 2OKN), two from unknown source (PDB: 3N2C, 3MKV), 
two from Alteromonas sp. (PDB: 3L7G, 3L24) and the other one from Pyrococcus furiosus 
(PDB: 1PV9).  Through studies on the crystal structures of native Pyrococcus furiosus prolidase 
(Pfprol) and its complex with inhibitor (2S, 3R)-3-Amino-2-Hydroxy-5-methyl-hexanoyl-proline 
(AHMH-pro), Maher et al. (2004) elucidated the detailed structure of the active site and how  
  
24 
 
 
 
 
Figure 2.3-3  Model of allosteric regulation driven by entropy. 
Panel A: Allosteric activation pathway of WT-CAP; cAMP binding to WT-CAP elicits the active 
conformation so that DBD becomes structurally poised to interact favourably with DNA.  
Complex formation is strongly enthalpically favoured and entropically unfavourable.  Panel B: 
allosteric activation pathway of CAP-S62F; cAMP binding to CAP-S62F, active 2 % of the 
protein.  DNA affinity is different between active and inactive conformations of CAP by many 
orders of magnitude.  DNA will bind selectively to the sporadic, active DBD and shift the 
population from the inactive DBD to the active DBD conformation. DNA binding to CAP-S62F-
cAMP2 is entirely driven by entropy, which is dominated by conformational entropy.  The red 
arrows indicate the allosteric transition undergone by DBD.  The pictures are reproduced from 
Tzeng and Kalodimos (2009) 
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Pfprol discriminates against oligopeptides and in favour of Xaa-Pro substrates.  Pfprol is a 
homodimer with a subunit molecular mass of 39.4 kDa and its polypeptide fold of a subunit was 
shown in Figure 2.4-1-A.  The subunit has two domains (domain I, residues 1-112; domain II, 
residues 124-348) and α-helical linker (residues 113-123).  The active site is located in an oval 
depression on the inner surface of a curved β-sheet of domain II.  In consistency with the active 
centre described above for metallopeptidase, in Pfprol, the dinuclear zinc atoms are bridged by 
Asp
220
, Glu
327
 and a solvent water (W
176
), as well as coordinate by the side chains of residues 
Asp
209
, Glu
313
, and His
284
, as shown in Figure 2.4-1-B and in Figure 2.4-1-C (yellow colour).  
The P1 binding site in Pfprol is formed by hydrophobic residues Phe
178
, Ile
181
, Ile
290
 and by Leu
37
 
(red colour in Figure 2.4-1-C). The binding site for proline (P1‟) is lined by His
280
, Tyr
317
, and 
Arg
325
 (blue colour in Figure 2.4-1-C).  They also indicated that two polypeptide segments, 
which are two loops (residues 291-300 and residues 36-39) as shown in Figure 2.4-1-C, can fold 
down toward the active site.  They argued that the proximity of these loops to the dinuclear metal 
site in Pfprol accounts for the preferences of the enzyme for dipeptide substrates (Maher et al., 
2004).   
Llaprol shares 61.9 % similarity with Pfprol at the amino acid level, as demonstrated in the 
alignment in Figure 2.4-2.  Thus, Dr. Tanaka‟s research group constructed sequence-based 
computer model of Llaprol on the basis of Pfprol crystal structure (Yang and Tanaka, 2008).  To 
clarify the unique properties possessed by Llaprol, such as substrate specificity, and allosteric 
behaviour, Zhang et al. (2009) examined the importance of Arg
293
, His
303
, and Ser
307
 through the 
studies on their mutants, and they indicated Arg
293
 besides the active centre (Figure 2.4-3) is an 
important residue contributing to the allosteric behaviour and substrate inhibition of Llaprol.  Hu 
and Tanaka (2009) further tested the roles of Phe
190
, Leu
193
, and Val
302
, which are corresponding  
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Figure 2.4-1  Models of important residues in Pfprol. 
Panel A: The structure of a monomer of Pfprol. Ribbon drawing highlighting the domain 
structure; N-terminal domain is in blue and the C-terminal domain is yellow. The Zn atoms are 
shown as gray spheres. Panel B: the active centre of Pfprol; Metal atoms in Pfprol are cobalt. 
The positions of coordinated amino acid residues are labelled.  Panel C:  Active site residues are 
coloured gold yellow and the metal ions are coloured gray sphere; besides the active centres, 
substrate binding sites S1 and S1‟ are coloured in red and blue. Above the active centre, a loop 
structure (position-33 to 40) is shown in a ribbon model.   
 
 
 
 
His280 
Tyr317 Arg325 
Leu37 
Ile181 
Ile290 
Phe178 
His284 
S1 
S1
’ 
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Figure 2.4-2  Alignment of the amino acid sequences of Llaprol and Pfprol.  
The sequences showed in red colour are the consensus sequence between primary sequence of 
Llaprol and Pfprol.  The red frame indicates the loop segments in both prolidases; the blue frame 
indicates the position 293 in Llaprol and the corresponding residue in Pfprol; the green stars 
represent the metal-chelating residues in both prolidases.  Black and purple arrows indicate the 
S1 site and S1
‟
 site residues, respectively.  The amino acid sequences were obtained from NCBI 
(GenBank accession code for Llaprol: EU216565; PDB accession code for Pfprol: 1pv9) and 
aligned using Clustal W (Thompson et al., 1994). 
 
 
 
 
 
Llaprol 
 
Pfprol 
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Figure 2.4-3  The loop structures and active sites in Llaprol and Pfprol.   
Panel A: The active site is around two metal atoms (gray spheres).  The thick and thin lines 
represent the Llaprol and Pfprol, respectively.  S1 and S1‟ residues are coloured blue (Phe
190
, 
Leu
193
 and Val
302
) and green (His
292
, Tyr
329
, and Arg
337
), respectively.  Chelating residues are 
shown in cyan.  Substrate size-limiting residues (Pro
306
, Ser
307
 and lle
308
) are shown in orange.  
Above the active sites, loop structures of Pfprol (yellow) and Llaprol (cyan) are shown.  The 
Panel B: A computer model of the active site and Loop
32-43
 in Llaprol.  Allosteric determing 
residue Arg
293
 is coloured purple, chelating residues are illustrated in cyan, and the four charged 
residues on Loop
32-43
 are labelled.   
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to Phe
178
, Ile
181
, and Ile
290
, in the S1 site of Pfprol.  Results from this study demonstrated Leu
193
 
and Val
302
 contribute the hydrophobic pocket of substrate binding site and they can interact with 
Arg
293
 to influence the allostery.  Besides, they also suggested His
296
 corresponding to His
284
 in 
Pfprol is the proton acceptor in the catalysis, which participate in the catalytic process as 
mentioned in section 2.2.1.  Protonated His
296
 stabilizes the intermediate stage when the metal 
bound hydroxide attacked the peptide bond of substrates. 
These two reports about Llaprol also indicated that a Loop
32-43
 structure near the active site 
would contribute to the unique characteristics, i.e., allosteric behaviour and substrate inhibition.  
They also illustrated that a notable difference in the active sites between Llaprol and Pfprol is the 
length of the loop structure that is contributed by the other subunit and cover the S1 site (as 
shown in Figure 2.4-3-A).  The longer loop in Llaprol is due to four charged residues (Asp
36
, 
His
38
, Glu
39
 and Arg
40
), which are located in the middle of Loop
32-43
 (as shown in Figure 2.4-3-
B). 
2.5 Loop Structure–Function Relationships 
-helices, -sheets and reverse turns are three common known secondary structures.  - 
helices and -sheets are termed as regular structures whereas reverse turns are considered as non-
regular structures.  In 1986, another type of non-regular secondary structures of protein was 
categorized as the protein loop.  The protein loop, defined as a segment of contiguous 
polypeptide chain that traces a “loop-shaped” path in the three-dimensional space, is proposed to 
be a novel category of non-regular secondary structure (Leszczynski and Rose, 1986).  Since 
then, loop structures have been emerging as functionally important components in proteins.  
These functional loops are observed in a wide range of enzymes such as aspartic proteinases, 
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glutathione synthetase, tryptophan synthase, adenylate kinase, lactate dehydrogenase, and 
ribulose-1,5-bisphosphate carboxylase.   
In aspartic proteinase, a loop commonly known as a "flap" is found to extend over the active 
site and is implicated in the catalytic process (Kempner, 1993; Sielecki et al., 1990).  This flap 
opens to allow substrate access to the active site cleft, closes on substrate bindings and opens 
again to allow products to leave.  Aguilar et al. (1997) found that, in Saccharomyces cerevisiae 
proteinase A crystal structure, a loop
72-81
 extends over the active site that has been implicated in 
catalysis.  Li et al. (2000) reported this loop region of Saccharomyces cerevisiae proteinase A is 
the most flexible portion.  The largest conformational change observed among different 
structures of this enzyme is up to 8.7 Å.  Moreover, polypeptide residues ~Tyr-Gly-X-Gly~ on 
this loop are highly conserved among aspartic proteinases from different sources.  In pepsin, a 
corresponding Loop
71-80 
with Tyr
75
-Gly
76
-Thr
77
-Gly
78
-Ser
79
 at its tip, locates near the active site 
and changes its position upon substrate binding.  Tyr
75
 participates in substrate alignment and 
anchors the flap in pepsin (Tanaka et al., 1998).  Thr
77
 is responsible for forming hydrogen bonds 
with substrates and for constructing a proper geometry in a transition state during the catalysis 
(Okoniewska et al., 1999).  Gly
76
 and Gly
78
 act as the hinges of the flap to enable Thr
77 
at the tip 
of the flap to form hydrogen bonds with active site residues (Okoniewska et al., 2000). 
A flexible loop (Ile
226
-Gly
242
) in Escherichia coli B glutathione synthetase stabilizes the 
acylphosphate intermediate by preventing its decomposition with water (Tanaka et al., 1992; 
1993).  They hypothesized that the flexible loop extends over the bound substrates in the active 
site, moving from an “open” position in the unliganded enzyme into a “closed” position when 
substrates bind to the active site of the enzyme.  Subsequently, Kato et al. (1994) constructed and 
crystallized a loopless mutant to investigate the function of the loop in the Escherichia coli 
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enzyme.  They found the crystal structure of the loopless mutant is similar to that of the wild 
type while the activity of the loopless mutant is 3х104 less than that of the wild-type enzyme.  
These studies elucidated that the loop has a hyperfunction that is not only a stabilization of the 
transition states and/or the intermediate of the reaction but also the coupling of ATP hydrolysis 
with glutathione synthesis through the recognition of the substrates. 
Recently, Christen et al. (2008) proposed that residue Ser
170
, located on a β2–α2 loop in 
mouse prion protein, has a marked impact on the conformational properties.  Hu et al. (2008) 
speculated that an active site loop of diaminopimelate decarboxylase from Helicobacter pylori 
cycles through down- and up-conformations to stabilize catalytic intermediates and releases 
reaction products, respectively.  These studies demonstrated essential roles of the loop structure 
play in the process of the enzymatic catalysis. 
2.6 Protein X-ray Crystallization 
In the late 1950‟s, Kendrew et al. (1958) solved a crystal structure of sperm whale 
myoglobin, for which Max Perutz and Sir John Cowdery Kendrew were awarded the Nobel Prize 
in chemistry in 1962.  Since then, up to July 8, 2010, more than 57,402 crystal structures of 
proteins, nucleic acids and other biological molecules were determined by using X-ray 
crystallography, while 8,482 structures were solved using NMR, which is normally applied to 
relatively small proteins with less than 300 amino acid residues (Smialowski et al., 2006).  X-ray 
diffraction methods have provided experimental basis of our present knowledge of protein 
structures, and they also have been proven as one of the most convincing approaches in 
investigations of enzyme mechanism. 
X-ray is electromagnetic waves that have a wavelength of between 10
-7
 and 10
-10 
m.  X-ray 
waves are scattered when they hit electrons of atoms.  It is similar to the way that light waves are 
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scattered by the engraved lines of a diffraction grate.  The regular lattice of a crystal acts like a 
three-dimensional diffraction grate in scattering a monochromatic beam of X-rays. 
A protein crystal has many unit cells with three-dimensionally ordered repeats.  Each cell is 
composed of more than 100,000 electrons.  The electron distribution in each cell can be 
considered as „electron clouds‟ localized at the atoms of protein molecules.  As shown in Figure 
2.6-1-A, when X-ray interacts with electron clouds in a protein crystal, the electric components 
of the X-ray exert a force on the electrons.  This causes the electrons to oscillate with the same 
frequency as the incident X-ray.  The oscillating electrons emit radiations with the same 
frequency as the incident radiation.  The scattered waves interact with each other creating a 
diffraction pattern (Figure 2.6-1-B).  The distribution of diffraction spots reflects the geometry of 
the unit cell, when relative intensities of the diffracted spots are used in the Fourier 
transformation to obtain electron density into which a model of the molecule is fitted.  However 
to elucidate the electron density, we need to identify phases of all diffraction spots.  One of these 
known methods of obtaining phases is molecular replacement (MR), letting a model of known 
molecule to fit into the unit cell of an unknown structure.  Afterwards, the electron-density map 
based on this initial phases is interpreted to produce an atomic model of the molecule via a 
function as shown in Figure 2.6-1-B.  In this way, the three-dimensional structure (the 
coordination of the atoms in the space) of unknown molecular can be interpreted.   
The accuracy of obtained structures depends on both the quality of protein crystals and the 
resolution of their diffraction.  Since a resulting electron density map is an average of all the 
molecules within the protein crystal, the uniformity of unit cells in the crystal influences the 
accuracy of the final model.  In addition, how far between the atoms in molecules can be  
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Figure 2.6-1  Schematic view of the process of protein X-ray diffraction 
A: The photography presents a diffractometer, an equipment to collect protein X-ray diffraction, 
at Canadian Light Source.  X-ray beamline, beam stop, N2 stream, area detector and the place 
where the protein crystal situated are indicated in the photo.   
B: The diffraction spots showed on the area detector are used to obtain amplitudes and phases of 
the molecule via Fourier transformation.  The inset function is used to calculate the electron 
density of a target molecule.  In this function, V is the volume of the unit cell; F(h,k,l) and 
(h,k,l) are the amplitudes and phases of the molecules, respectively.  (x,y,z) is the electron 
density of the molecule.This picture is adapted from www.xtal.iqfr.csic.es/.  
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distinguished (defined as the resolution) is also important for accurate interpretation of the 
crystal structure.  At a low resolution, 4 to 6 Å, the electron density map reveals just a little more 
than the overall shape of the molecule in most cases.  At 3.5 Å, it is often possible to follow the 
polypeptide backbone, but there might be some ambiguous regions.  At 3.0 Å, it is possible to 
begin to resolve the amino acid side chains, and with some uncertainty, to fit the sequence to the 
electron density.  At 2.5 Å, the position of atoms may often be fitted with an accuracy of ±0.4 Å. 
In order to locate atoms within 0.2 Å accuracy, a resolution at 1.9 Å or less is necessary (Fersht, 
1985). 
To determine the three-dimensional structure of a protein using X-ray crystallography, the 
first requirement is obviously to grow crystals of good qualities.  Crystallization is a complex 
and multi-parametric process, which produces high quality well-ordered crystals is a 
predominant bottleneck in the structure determination.  The phase diagram in Figure 2.6-2 
illustrates the crystallization process, which is associated with the states (liquid, crystalline, or 
precipitate) with several parameters.  Chayen and Saridakis (2008) distinguished the diagram in 
four areas: an area of very high supersaturation, where the protein will precipitate; an area of 
moderate supersaturation, where the protein will nucleate spontaneously; an area of lower 
supersaturation below the nucleation zone, where crystals are stable and may grow (this area is 
thought to contain the best conditions for growth of larger, well-ordered crystals); and an 
understaturated area, where the protein will never crystallize.  The choice of the method depends 
on the protein species.  Crystallization phase diagrams (Figure 2.6-2) can be used to understand 
the design of experiments.  Each method forces protein solution to reach the nucleation zone and 
then the metastable zone through different routes (dashed lines).   
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Figure 2.6-2  Schematic illustration of a protein crystallization phase diagram. 
Adjustable parameters include precipitant or additive concentration, pH and temperature. The 
four major crystallization methods are represented: (i) microbatch method, (ii) vapour diffusion, 
(iii) dialysis and (iv) FID.  Yellow dashes and arrows illustrate the crystallization process of each 
method.  (adapted from Chayen and Saridakis (2008)) 
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Several methods, such as vapour diffusion, microbatch, dialysis, free interface diffusion, 
and in-gel crystallization are available for making protein crystals.  Each method has its 
advantages and disadvantages.  The batch method achieves supersaturation immediately upon a 
mixing, whereas all the other diffusion-based methods gradually bring the protein solution from 
undersaturation to supersaturation by equilibration with a solution containing the crystallizing 
agents at target concentrations. 
Vapour diffusion is a common method of crystallization. The protein solution is either a 
hanging or sitting drop that equilibrates in a closed container against the mother liquor which 
contains higher or lower concentrations of crystallizing agents than those in the drop. The 
conditions change gradually until the drop and the mother liquor reach equilibrium.  Trials are 
normally conducted in 24-well plates, where each well holds a 0.5-1 mL reservoir solution and is 
sealed with a siliconized glass or plastic coverslip.  The wells are fitted with a support for the 
sitting drop while hanging drops are hung from the coverslip.  A concentrated pure protein at 5- 
15 mg/mL is usually employed.  The advantage of this method is that this method provides a 
convenient way to adjust conditions precisely in a very small sample.  The drawback of this 
method is the occurrence of skin formation on hanging drops during the diffusion process. 
In dialysis methods, a semi-permeable membrane is employed to allow mixing the protein 
solution gradually, and the protein crystal is obtained from the protein solution, as shown in 
Figure 2.6-3-B.  Typical procedures include the use of a dialysis bag, dialysis buttons or 
zepperzauer microdiffusion cells.  In some cases, the burden of the gradient across the dialysis 
membrane can result in limiting the number of crystal nucleation sites and reducing the sizes of 
the protein crystals.  Thomas and Pritchard (1987) employed a 'double-dialysis' procedure, which  
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Figure 2.6-3  Schematic Illustrations of Different Crystallization Approaches. 
A: Hanging drop vapour diffusion; B: Button dialysis; C: Microbatch; D: FID; E: In-gel 
crystallization.  Protein solutions and screening solution are presented in red and blue, 
respectively.  The materials used for sealing the crystallization condition are coloured yellow.  
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incorporates a second dialysis membrane to reduce the rate of equilibration in the crystallization 
experiment.   
In microbatch experiments as shown in Figure 2.6-3-C, crystallization trials are dispensed 
and incubated under low-density paraffin oil.  The microbatch method can be used for almost all 
known precipitants, buffers and additives, including detergents, glycerol and ethanol.  It can not 
be used for crystallization trials containing small organic molecules such as phenol, dioxane or 
thymol because these molecules dissolve into the oil.  Robots can dispense thousands of 
microbatch trials in small volumes.  Depending on the type of oils used, this technique can be 
harnessed for screening, fine-tuning and optimization experiments.  Robotic systems have been 
employed in obtaining protein crystals (Kelders et al., 1987; Perozzo et al., 1988).  A large 
concern of this automatic procedure was the requirement of relatively large volumes of protein 
(at least 1-2 μL).  Chayen (1990) reported a microbatch automatic system, which routinely 
dispenses 0.2-1 μL protein, with a final droplet volume of 2 μL. 
Free interface diffusion (FID) is a process in which a low-density solution is layered onto a 
high-density solution.  As shown in Figure 2.6-3-D, the two fluids are allowed to mix by direct 
contact and to reach equilibrium gradually.  FID has not been widely used because it requires the 
use of capillary tubes.  To conduct this experiment, 2 to 5 L of protein sample was transferred 
into a microcapillary, then 2 to 5 L of precipitant was slowly loaded into this microcapillary 
without introducing an air bubble, and the ends are sealed with the wax or clay for crystallization.  
The advantage of this method is that it requires less purified protein and it also generates protein 
crystals faster and more cost effectively (Yanicek, 2003). 
In-gel crystallization is a crystallization method relying on the microgravity.  In comparison 
of ground-based experiments, the protein crystals grown under microgravity conditions in the US 
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Space Shuttle Mission STS-95 were more ordered (Boggon et al., 1998).  Lorber et al. (1999) 
observed that the crystals grown in gel on earth, mimicking the microgravity in the space, 
yielded better crystals obtained in solution.  Biertumpfel et al. (2002) reviewed the technique of 
employing agarose gels in crystallization of biological macromolecules.  Sauter et al. (2009) 
employed agarose gel crystallization and analog of substrates to solve the three-dimensinal 
structure of aspartyl-tRNA synthetase, which supports the application of gels in the protein 
crystallization.  To perform this experiment, 1-2% agarose gel (low melting temperature) is 
mixed with screening solution in the ratio of 1:6.  The mixed solution is sucked into a capillary 
and sits until its solidification.  Five microliters of protein solution are added on the top of the 
solidified gel.  Lastly, both ends of the capillary are sealed for crystallization (Figure 2.6-3-E). 
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3 HYPOTHESIS AND OBJECTIVES 
The recombinant Lactococcus lactis prolidase (Llaprol), which is a 67-kDa homodimeric 
metalloenzyme with the isoelectric point (pI) of 4.6, shows interesting properties: allosteric 
behaviour and substrate inhibition (Yang and Tanaka, 2008).  To elucidate the enzyme 
mechanisms, structure-function relationship studies on Llaprol were performed in previous 
studies (Hu and Tanaka, 2009; Zhang et al., 2009).  Behaviours of allostery and substrate 
inhibition are not reported in other prolidases and these features are not fully elucidated in terms 
of their underpinning molecular mechanisms.  Direct or indirect manipulations on Arg
293
 cause 
the loss of allosteric behaviour and substrate inhibition of Llaprol, which suggest that Arg
293
 
located near the active site is a key residue to contribute these unique features of Llaprol (Zhang 
et al., 2009).  From the molecular modelling study, Loop
32-43
 of a subunit located above the 
active site of the other subunit was proposed to play an important role in the allosteric regulation 
of Llaprol (Yang and Tanaka, 2008).  Loop
32-43
 of Llaprol is longer than that of non-allosteric 
Pyrococcus furiosus prolidase (Pfprol) by four residues.  Interestingly, this difference is observed 
as an addition of four charged residues: Asp
36
, His
38
, Glu
39
, and Arg
40
 on this loop, whereas 
Pfprol does not have charged residues on the corresponding loop.  These facts suggest that the 
Loop
32-43
 can be stretched and its charged residues may offer distinctive properties observed in 
Llaprol.   
The hypothesis of this study is that the charged residue(s) on Loop
32-43
 contributes to the 
allosteric behaviour and substrate inhibition through interactions with Arg
293
 and/or other active 
site residues.  This hypothesis was examined through the analysis of Llaprol mutants. Also, it 
will be necessary to know the actual three-dimensional structure of Llaprol in order to interpret 
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the results from this and future research.  Thus a crystallographic study of Llaprol was also 
initiated. 
The objectives of this project are as follows: 
i) To elucidate the contributions of Loop
32-43
 by means of a loopless mutant,   
ii) To identify the roles of individual residues on the loop structure, and   
iii) To crystallize Llaprol for X-ray crystallography.   
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4 MATERIALS AND METHODS 
4.1 Materials 
pUC18 and pKK223-3 vectors were used for construction and expression of the mutated 
Llaprol genes.  E. coli TOP10F‟ (F'[lacIq Tn10(tetR)] mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 deoR nupG recA1 araD139 Δ(ara-leu)7697 galU galK rpsL(StrR) 
endA1 λ-) was used as the cloning and expression host in this project.  These vectors and host 
were supplied from the lab collection of Dr. Tanaka‟s laboratory.  All the oligonucleotides 
required in this research were synthesized at Integrated DNA Technology (IDT; Coralville, IA, 
USA).  Restriction enzymes were purchased from Fermentus International (Burlington, ON, 
Canada).  DNA Pfu polymerase, dNTPs and T4 DNA ligase were obtained from Invitrogen 
(Burlington, ON, Canada).  Peptone and yeast extract were products of BD (Franklin Lakes, NJ, 
USA).  ATP was obtained from EMD Chemicals (Darmstadt, Germany).  IPTG was bought from 
Omega Bio-Tek (Norcross, GA, USA).  Protein Assay Dye Reagent Concentrate was purchased 
from Bio-Rad (Hercules, CA, USA).  Arg-Pro, Pro-Pro, Asp-Pro, Glu-Pro，Leu-Leu-Pro and 
Leu-Val-Pro were synthesized at GenScript (Piscataway, NJ, USA).  Leu-Pro and Lys-Pro were 
purchased from Bachem (Torrance, CA, USA).  Phe-Pro and Val-Pro were products of Sigma 
(Oakville, ON, Canada).  Gly-Pro was obtained from Peptide Institute Inc. (Ibaraki, Osaka, 
Japan).  All other common chemicals are at ACS-grade or better, and obtained from Sigma 
(Oakville, ON, Canada), EMD Chemicals (Darmstadt, Germany), Fisher Scientific (Ottawa, ON, 
Canada), and Alfa Aesar (Massachusetts, MA, USA). 
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4.2 Site-Directed Mutagenesis 
E. coli TOP10F‟ harbouring the Llaprol gene on a pUC18 plasmid (pUC-lacQ) had been 
constructed in a previous study of Dr. Tanaka‟s laboratory (Yang and Tanaka, 2008).  Modified 
Quik-Change site-directed mutagenesis (SDM; Braman et al., 1996) was employed to perform 
mutagenesis on the pUC-lacQ.  This method synthesizes mutated DNA with a pair of mutation 
primers via PCR.  pUC-lacQ plasmid DNA was purified with an alkalysis method (Birnboim and 
Doly, 1979) and used as the template DNA.  Besides 50~100 ng template DNA, the reaction 
mixture of the PCR contained a pair of oligonucleotides (20 pmol each), 10 pmol of each dNTPs, 
and 0.5 units of Pfu DNA polymerase.  The reaction mixture was incubated in a PCR machine 
with 16 cycles of 1 min-95 °C/1 min-55°C/4 min-68°C along with the 5 min denaturation at 
95 °C prior to these cycles and a 10 min elongation period at 72°C after the cycles.  The primer 
pairs to construct each mutant are listed in Table 4.2-1.  The PCR products were treated with 10 
L of chloroform, followed by an ethanol precipitation.  The resultant DNA molecules were 
digested with the Dpn I restriction enzyme in order to degrade the template DNAs, and further 
transformed into E. coli TOP10F'.  Transformants were spread on LB agar plates and incubated 
at 37 °C overnight.  Colonies were picked up and their plasmid DNAs were digested with the 
restriction enzyme that recognizes the sequence incorporated with the oligonucleotides primers 
(as shown in Table 4.2-1) to identify positive clones for each mutants.  The positive clones were 
further confirmed using DNA sequencing with M13 universal primers (shown in Table 4.2-1) at 
National Research Council-Plant Biotechnology Institute (Saskatoon, SK, Canada).  A double 
mutant (D36E/R293K) was constructed by introducing R293K mutation on the confirmed D36E 
mutant gene.  Following to the screening, positive clones were subcloned into an expression 
system.  The mutated prolidase genes in the positive clones were PCR-amplified using two  
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Table 4.2-1  List of primers used in this study. 
 
Primers Sequences (5‟ to 3‟) Restriction 
enzymes 
 F: ACAGGGCTAGCAATTATTGCCGGCCTGATG 
R: CATCAGGCCGGCAATAATTGCTAGCCCTGT 
Pdi I 
D36S F: CTAGCAATTTCTCCTCATGAACGAATTG 
R: CAATTCGTTCATGAGGAGAAATTGCTAG 
Pag I 
H38S F: GCTAGCAATCGATCCCAGTGAACGAATTG 
R: CAATTCGTTCACTGGGATCGATTGCTAGC 
Cla I 
E39S F: GATCCCCATTCGCGAATTGCTGG 
R: CCAGCAATTCGCGAATGGGGATC 
Nru I 
R40S F: CCCCATGAATCGATTGCTGGG 
R: CCCAGCAATCGATTCATGGGG 
Cla I 
R40E F: GCAATTGATCCTCATGAAGAAATTGCTGGG 
R: CCCAGCAATTTCTTCATGAGGATCAATTGC 
Pag I 
R40K F: GCAATTGATCCTCATGAAAAAAATTGCTGGG 
R: CCCAGCAATTTTTTCATGAGGATCAATTGC 
Pag I 
D36S/E39S F: CTAGCAATTTCTCCCCATTCGCGAATTGCTGG 
R: CCAGCAATTCGCGAATGGGGTGAAATTGCTAG 
Nru I 
H38S/R40S F: GCAATTGATCCCAGTGAATCGATTGCTGGG 
R: CCCAGCAATCGATTCACTGGGATCAATTGC 
Cla I 
D36E 
 
F: CTAGCAATTGAACCTCATGAACGAATTG 
R: CAATTCGTTCATGAGGTTCAATTGCTAG 
Pag I 
R293K F: GAATATTTCAATCACAAGCTTGGACATGG 
R: CCATGTCCAAGCTTGTGATTGAAATATTC 
Hind III 
LacQ F: GGAGAATTCATGAGCAAAATTGAACGTATT 
R: ATTCTGCAGTTAGAAAATTAATAAGTCATG 
EcoR I 
Pst I 
M13 F: GTTGTAAAACGACGGCCAGT 
R: CACAGGAAACAGCTATGACC 
None 
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Sequencing 
pKK223-3 
F: GCTGTTGACAATTAATCATCGGC 
R: TACTGCCGCCAGGCAAATTC 
None 
Note: Underlined sequences indicate newly-created restriction enzyme sites for identification of 
mutant genes. 
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primers (LacQ-F and LacQ-R; Table 4.2-1).  Twenty picomoles of each primer were used in the 
PCR reaction with 10 ng of mutated pUC-lacQ DNA, 10 pmol of each dNTP, and 0.5 units of 
Pfu DNA polymerase for a total of 50 L mixtures.  The reaction mixture went through 30 
cycles of 1 min-95 °C/ 1 min-55 °C/ 1 min-72 °C along with the 5 min denaturation at 95 °C 
prior to these cycles and a 10 min elongation period at 72 °C after the cycles.  The PCR products 
underwent EcoR I and Pst I restriction enzyme digestions to generate adhesive ends, along with 
Dpn I restriction enzyme digestions to remove methylated parental DNAs.  The DNA fragments 
of the resultant mutated Llaprol gene were ligated into EcoR I/Pst I digested pKK223-3 plasmids. 
The ligation mixtures were transformed into E. coli TOP10F'.  Plasmid DNAs were extracted 
from the resultant colonies and further digested with the Nde I and Pst I restriction enzymes.  
The positive clones were identified to show 3.2 and 2.1 kb fragments on the 1 %-agarose gel 
electrophoresis.  The positive mutated pKK223-3-lacQ DNA molecules were confirmed via 
DNA sequencing using pKK223-3 vector primers (Table 4.2-1) and the confirmed E. coli clones 
were stored in glycerol solution (30 % (w/v)) at -80 °C for future uses.   
4.3 Expression and Purification of Llaprol Mutants 
Standard procedures according to a previous study by Dr. Tanaka‟s group (Yang and 
Tanaka, 2008) were implemented to express and purify the Llaprol mutants.  The pKK223-3 
clones were inoculated into acidic Luria-Bertani Broth (LB, pH5.5, 900 mL shared equally in 
nine 500-mL flasks) containing 150 g/mL ampicillin and the inoculated broth was vigorously 
shaken (200 rpm) at 16 °C.  To induce the recombinant protein production, IPTG was added at a 
final concentration of 1 mM to the broth when the optical cell density at 600 nm reached 0.5.  
The culture was then resumed for additional 72 hours.  Cells from the 900-mL culture were 
harvested through centrifugation (Sorval SS-34, 6,000 ×g, 4°C, 10 min) and were suspended into 
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10 % (w/v) of a 20 mM sodium citrate (pH 6.0)/1 mM zinc chloride/50 mM sodium chloride 
solution.  The suspended cells underwent ultrasonication to release the soluble molecules, 
followed by centrifugation (Sorval SS-34, 12,000 ×g, 4°C, and 20 min).  The supernatant was 
brought to 40 % saturation of ammonium sulfate and kept on ice for 1 hour to precipitate most of 
nucleic acids and some proteins, which were then removed with centrifuging (Sorval SS-34, 
12,000 ×g, 4 °C, and 20 min).  The resultant supernatant was brought to 60 % saturation of 
ammonium sulfate and was kept on ice for at least 5 hours.  After centrifuging (Sorval SS-34, 
12000 ×g, 4 °C, and 20 min), Llaprol mutants were recovered as centrifugal pellets.  The 
recovered mutant pellets were dissolved in a 3-mL Buffer A solution (20 mM sodium citrate (pH 
6.0)/1 mM zinc chloride).  The dissolved protein solution was transferred into a dialysis bag, and 
then the bag was dialyzed against an 800-mL Buffer A solution for 1 hour at 4 °C.  The dialysis 
was further conducted in a 2-L Buffer A solution for overnight at 4 °C.  The protein solution was 
centrifuged (Sorval SS-34, 12,000 ×g, 4 °C, and 20 min) to remove insoluble matter.  The 
supernatant collected following centrifugation (Sorval SS-34, 12,000 ×g, 4 °C, and 20 min) was 
applied on a DEAE Sephacel column (2.5 Φ × 20 cm, GE Health Sciences, Little Chalfont, 
Buckinghamshire, UK) equilibrated with Buffer A.  Llaprol mutants were eluted from the 
column with a 0 to 0.5 M sodium chloride linear gradient in Buffer A.  The fractions containing 
prolidases were identified on 10% SDS-PAGE, and were concentrated to approximately 5 mL 
with an Amicon YM-10 ultrafiltration (Millipore, Billeric, MA, USA).  The condensed sample 
was loaded on a DEAE 8HR column (Waters, Milford, MA, USA) equilibrated with Buffer A 
solution.  A NaCl linear gradient from 0 M to 0.5 M was used to elute proteins from the column.  
The fractions containing prolidase were combined after the identification with 10 % SDS-PAGE, 
and further concentrated with an Amicon YM-10 ultrafiltration.  The dimer formations were 
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examined by estimating the molecular mass through gel filtrations using Bio-Gel P-60, Sephadex 
G-100, G-150 and Bio-Gel P-200 as described by Yang and Tanaka (2008).  The purified 
prolidases were kept as 50 % glycerol solutions and stored at -20°C for future analysis. 
4.4 Enzyme Concentration Determination 
To determine protein concentrations during the purification process, a Bradford method 
(Bio-Rad Protein Assay Dye Reagent Concentrate, Hercules, CA, USA) was employed in this 
study.  In this method, 800 L of each sample were mixed with 200 L of the dye reagent 
concentration, and was incubated at room temperature for at least 5 minutes.  The optical 
absorbance of the samples was then detected at 595 nm using a spectrophotometer Beckman 
Coulter DU800 (Fullerton, CA, USA).  To generate a standard curve of this method, bovine 
serum albumin (BSA) was used as a standard and the standard BSA samples were prepared in 
triplicate at several known concentrations (1.2 to 10.0 g/mL).  The standard relationship 
between BSA concentrations and ABS595 was obtained as the following equation. 
[Protein] (mg/mL) =21.68ABS595 - 0.338   (Equation 4.4-1) 
To determine the protein concentration of mutated Llaprols, the protein samples were 
diluted to yield the absorption which falls into the range used to determine the standard curve. 
4.5 Enzyme Activity Assay 
The prolidase activity was measured using a ninhydrin method (Doi et al., 1981) that 
determines liberated proline via colourimetric spectrograph.  In this method, free proline, which 
was released from the prolidase reaction, reacted with ninhydrin to generate a chromophore 
detected as ABS515, while other amino acids are not able to initiate chromophore developing 
under these conditions.  The ninhydrin solution was prepared as 3 g ninhydrin dissolved in a 
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100-ml organic solvent containing acetic acid and phosphoric acid in a volume ratio of 6 to 4, 
and heated to 70 °C to dissolve ninhydrin completely.  A standard curve between different 
concentrations of free proline and ABS515 showed a linear relation, and we determined a 
coefficient of the proline-ninhydrin chromophore as 0.72555 M-1. 
The standard activity assay was conducted as follows: a 90 µL reaction mixture (RM; 20 
mM sodium citrate (pH 6.5)/1 mM zinc chloride/ 2.222 mM Leu-Pro substrate) was preheated at 
50 °C for 2 min.  Then, 10-µL enzyme preparation was added to RM to initiate the reaction, 
which dilute the substrate concentration to 2.0 mM.  At every 1 min (for 4 min), a 20-µL aliquot 
was sampled and mixed with a 100-L ninhydrin solution.  The mixture was heated at 100 °C for 
10 min and then chilled on ice.  The absorbance values of the samples were detected as ABS515 
using a Beckman Coulter DU800 spectrophotometer.  To generate accurate data, specific 
dilutions of prolidases were determined to accommodate the absorption changes up to 1.0 during 
the measurements.  The obtained absorbance was converted into the amount of free proline in the 
samples by multiplying with the coefficient (0.72555 M-1).. 
4.6 Determination of Kinetic Parameters 
Kinetic parameters were examined with reactions at various Leu-Pro concentrations (0.1, 
0.2, 0.3, 0.4, 0.5. 0.7, 1.0, 2.0, 4.0, and 8.0 mM).  The reaction mixtures contained 20 mM 
sodium citrate (pH 6.5), 1mM zinc chloride, and Leu-Pro at an assigned concentration.  The 
reactions were performed following the standard procedure of enzyme activity assay.  Michaelis 
constant (Km) and maximum velocity (Vmax) for each prolidase mutant were preliminary 
determined using the method described by Sakoda and Hiromi (1976), and putative Hill 
constants were calculated as the slopes of the linear regression of an Ln(ν/(Vmax-ν)) − Ln(S) plot.  
These preliminary values were further applied to fit the S-data to Equation 4.6-1 using a proFit 
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program (www.quansoft.com) to determine Michaelis constant (Km), maximum velocity (Vmax), 
Hill constant (h), and inhibition constant (Ki).   
i
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            (Equation 4.6-1) 
4.7 Substrate Specificity 
To investigate the substrate specificity of mutant prolidases, 11 peptides (Leu-Pro, Phe-Pro, 
Val-Pro, Arg-Pro, Lys-Pro, Gly-Pro, Asp-Pro, Glu-Pro, Pro-Pro, Leu-Leu-Pro and Leu-Val-Pro) 
were examined as the substrate in prolidase reactions.  The reactions were conducted under the 
standard enzyme activity assay conditions (defined in section 4.5) in the presence of zinc ions 
using 2 mM assigned peptide substrate. 
4.8 Metal Ion Dependency 
The activities were assayed in the presence of manganese chloride and different substrates 
to examine the metal ion dependency.  This procedure is the same as the one described in the 
study of substrate dependency (section 4.7) except substituting 1 mM zinc chloride with 1 mM 
manganese chloride.   
4.9 pH Dependency 
In pH dependency study, the enzymatic reactions were performed at various pHs (pH 4.0, 
5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, and 10.0).  Most pHs required for the study (pH 5.0 to 9.0) 
were prepared by mixing 20 mM sodium citrate (pH 4.96) and 20 mM sodium borate (pH 9.23) 
at different ratios.  pHs 4 and 10 were achieved using 20 mM citrate-HCl and 20 mM sodium 
borate-NaOH buffer solutions, respectively.  The measurements were followed as the standard 
  
51 
enzyme activity assay procedure described in section 4.5.  The activities at each pH were 
expressed as the activity relative to that at pH 6.5. 
4.10 Thermal Dependency 
Thermal dependency is used to examine local structural changes of the active site at 
different temperatures.  The reaction mixtures were incubated at a series of temperatures (20.0, 
30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, and 70.0 °C).  The constant temperature was controlled 
using a water bath and monitored using a digital thermometer.  The observed activities were 
expressed as relative values of the activity at 50 °C. 
4.11 Denaturation Temperature  
Thermal denaturation temperature can be an index of the overall structure changes.  Far 
UV-Circular dichroism (CD) spectrophotometer (PiStar-180, Applied Phytophysics Ltd 
Leatherhead, Surrey, UK) in Saskatchewan Structural Sciences Centre (SSSC) was employed to 
measure the thermal denaturation temperature by observing melting points of secondary 
structures of prolidase mutants.  To conduct this experiment, 1 mL of 1.0 mg/mL purified 
enzyme sample was filtered with a 0.25 m syringe filter and dilute with a buffer solution (20 
mM sodium citrate (pH 6.0)) at least 100 times to minimize the influence of pre-existing NaCl.  
The final solutions were concentrated to 0.8 mg/mL with a MicroSep column (MWCO 10 kDa; 
Pall Life Science, East Hills, NY, USA) at 8,000 rpm for 30 min using a Sorval SS-34 rotor.  
Four hundred microliters of each sample were used to perform CD.  The CD spectrum was 
measured over the temperature changes from 25 to 50 °C with increments of 5 °C, 50 to 80 °C 
with increments of 2 °C, and 80 to 90 °C with increments of 5 °C.  Data detected at the 
wavelength of 222 nm at different temperatures were used to plot the relationship between 
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temperatures and the angle of polarization (millidegrees (mdeg)).  From this plot, the 
denaturation temperature was defined as the temperature where the rate of change in CD signals 
reached its maximum which was calculated using Curve Expert 1.4 Program 
(http://curveexpert.webhop.net/). 
4.12 Prolidase X-ray Crystallography 
4.12.1 Sample Preparations 
To solve the three-dimensional structure of Llaprol, wild type Llaprol (WT) and loopless 
Llaprol (Δ36-40) were chosen for crystallization experiments.  For these experiments, Llaprol 
preparations were purified to 99 % homogeneity as determined on a 10 % SDS-PAGE gel.  Since 
salts such as sodium chloride are easier to crystallize than protein, the interference of these salts 
should be minimized during the protein crystallization.  To remove the excess sodium chloride 
used during the protein purification process, Buffer A (20 mM sodium citrate (pH6.5)/1 mM zinc 
chloride) was added to achieve at least 100 times dilution.  Then, the protein solution was 
reconcentrated into in a final concentration of at least 3.5 mg/mL in buffer A with MicroSep 
columns (Pall Corporation, NY, USA). 
4.12.2 Preliminary Crystallization Using Commercial Sparse Matrix Screening 
The initial screen solutions, Crystal Screen Kit 1 & 2 (Bukrinsky and Poulsen, 2001) were 
purchased from Hampton Research (Hampton Research, Aliso, Viejo, CA, USA).  The hanging 
drop vapour diffusion method (Figure 2.6-3-A) was employed in this study to crystallize WT and 
Δ36-40.  Trials were conducted in 24-well cell culture plates, where an 800-L reservoir solution 
from the Kit 1 or 2 was placed in the wells and siliconized glass coverslips were used to seal the 
wells.  These plates were kept on a shelf at room temperature for 1-3 weeks.  Observations on 
  
53 
these crystallization trials were regularly conducted using a microscope (Leica E-6E, Wetzlar, 
Germany) and recorded using a Sony camera.  This step was to primarily examine conditions 
(series pH, buffer, additive and precipitant) that WT or Δ36-40 may crystallize. 
4.12.3 Optimization of Crystallization  
Based on the results from above preliminary crystallization trials, several precipitants, salts, 
and buffer systems suitable for crystallizing WT and Δ36-40 were identified.  These conditions 
were further optimized to obtain crystals appropriate for X-ray diffraction.  Ten series (A to J) of 
cocktails were prepared according to the matrix design shown in Appendix A.  These series were 
conducted with varying single factor and fixing other factors.  Observations and recordings were 
performed to monitor the growth of crystals. 
4.12.4 X-ray Data Collection 
The sizes of crystals were measured using an ocular built-in ruler.  Crystals were then fished 
out using a mounting loop and performed room temperature X-ray diffraction measurements 
with a DX8 Proteum Diffractometer (Bruker, ON, Canada) at SSSC. 
A high brilliance beamline 08ID-1 of the Canadian Light Source (CLS) synchrotron was 
also employed to acquire a crystal structure of Llaprol with a high resolution.  X-ray diffraction 
in the CLS should be performed under cryoconditions in order to minimize the damage caused 
by the synchrotron beam; therefore, crystals should be protected by cryoprotectants.  
Cryoprotectants such as glycerol and PEG8000 were tested by means of a flash-freezing 
approach if they could protect crystals in liquid nitrogen.  In this approach, crystal screening 
solutions with different concentrations of glycerol or PEG8000 were tested as follows.  A small 
amount of these solutions were sampled one by one using a mounting loop and were 
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immediately put into liquid nitrogen for seconds.  Clear drop on the loop can be observed if the 
solution was suitable for cryoprotection.  Subsequently, crystals grown in this particular solution 
under the same conditions previously optimized in this study were brought into X-ray diffraction 
in the CLS. 
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5 RESULTS 
5.1 Preparations of Llaprol Mutants 
All of the Llaprol mutants (36-40, D36S, H38S, E39S, R40S, D36S/E39S, H38S/R40S, 
R40K, R40E, and D36E/R293K) were obtained at a homogeneity level.  In this section, D36S is 
representing to show the process and results of SDM, gene cloning and protein purification 
(Figure 5.1-1).  Using pUC-lacQ plasmid DNAs (size: 3.6 kb) as the template and D36S-F/R 
(Table 4.2-1) as the primers, mutated plasmid DNA harbouring ORF encoding D36S was 
obtained after SDM PCR as shown in Figure 5.1-1-A.  Resultant PCR products were transformed 
into E. coli TOP10F‟.  Positive clones of recombinant E. coli whose plasmid DNAs generated a 
3.6 kb single band after Pag I digestion as shown in Figure 5.1-1-B were identified to carry the 
mutated Llaprol gene and used for further subcloning.  Figure 5.1-1-C shows DNA fragments 
(1.0 kb) of the mutated gene acquired by PCR using primers LacQ-F and LacQ-R (Table 4.2-1).  
After ligation with digested pKK223-3 vectors, the positive samples were screened with EcoR I 
and Nde I digestions.  Positive clones showed 2.2 and 3.1 kb bands as shown in Figure 5.1-1-D. 
The identities of pKK223-3 clones were confirmed via DNA sequencing and these 
expression plasmids were transformed into E. coli TOP10F‟ cells to express recombinant 
Llaprols.  The purity and homogeneity of prepared mutant Llaprols were confirmed on a 10 % 
SDS-PAGE as shown in Figure 5.1-1-E.  Gel filtration tests exhibited the purified Llaprol 
proteins were between 60 and 100 kDa, indicating they form dimmeric structures as observed in 
WT.  
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Figure 5.1-1  Results of the preparation of D36S mutant. 
Panel A: SDM PCR result of D36S using pUC18-lacQ as templates; #1: DNA molecular weight 
marker; #2, 3: Products of SDM PCR, showing 3.6 kb bands.  Panel B: Pag I digestion to screen 
positive clones containing D36S mutation; #1: DNA molecular weight marker; #2, 3: negative 
controls; #4, 5: positive results, showing linearized plasmids.  Panel C: PCR result for the 
subcloning; #1: DNA molecular weight marker; #2, 3: PCR products showing 1.0 kb bands.  
Panel D: The EcoR I and Nde I digestion to screen pKK223-D36S; #1: DNA molecular weight 
marker; #2: a positive clone showing two bands at 2.2 and 3.1 kb; #3: A negative result;  Panel E: 
A SDS-PAGE gel showing the purified D36S; #1: Protein molecular weight marker; #2: Crude 
extract fraction of pKK223-D36S/E.coli TOP10F‟; #3: Dialyzed fraction after 60 % (NH4)2SO4 
precipitation; #4: DEAE-8HR purified D36S Llaprol. 
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5.2 Characterization of Llaprol Mutants 
5.2.1 Activity Assay of Llaprol Mutants 
Before being submitted to detailed enzyme characterizing studies, including [S]- plot, 
substrate specificity, metal ion dependency, pH dependency, temperature dependency and 
denaturing temperature analyses, all Llaprol mutants in this study were examined on their 
activities toward substrate Leu-Pro, which was the most preferred substrate for WT Llaprol.  
Among these mutants, 36-40, E39S, D36S/E39S, R40S, R40E, R40K and H38S/R40S were 
found inactive, and D36S, H38S, and D36E/R293K were active at various levels.  Thus, the 
seven inactive mutants were eliminated from further enzyme characterization studies.  However, 
these mutants indicated the Loop
32-43
, especially Glu
39
 and Arg
40
 on this loop, played important 
roles in maintaining the activity of Llaprol. 
5.2.2 Determination of Kinetic Parameters 
According to the methods aforementioned in section 4.5, velocities of each mutant were 
examined individually at a series of substrate (Leu-Pro) concentrations.  The relationship 
between the reaction rates and substrate concentrations of each mutant is presented in Figure 5.2-
1 as the [S]-plots.  The D36S mutant showed a hyperbolic curve up to 4 mM, implying a loss 
of the allostery in D36S that low concentrations of substrates did not suppress the reaction rates 
(Figure 5.2-1-B).  In a contrast, the H38S mutant showed a sigmoidal curve where its reaction 
rate slowly increased at a range of low substrate concentrations (Figure 5.2-1-C).  This was an 
indication of the existence of the allosteric behaviour, which is a distinctive property of WT 
(shown in Figure 5.2-1-A).  The h, Km, Ki, and Vmax values for each mutant were summarized in 
Table 5.2-1.  The Hill constant of H38S was 1.52 which was close to that of WT (1.58) while  
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Figure 5.2-1  [S]-plots of Llaprol mutants measured using Leu-Pro as the substrate. 
A) WT, B) D36S, C) H38S, D) D36E/R293K.  The velocity is expressed as the specific activity 
(mol/min·mg).  The line in each plot shows the calculated relation of [S] and v according to 
Equation 4.6-1. 
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Table 5.2-1  Kinetic parameters of mutant and WT Llaprols. 
 
 Vmax (mol/min·mg) Km (or K0.5) (mM) Vmax /Km h Ki (mM) 
WT
a
 1740 8.0 217.3 1.58 15.3 
D36S 1673.3 3.4 496.3 0.90 12.6 
H38S 178.3 1.3 134.1 1.52 1162.5 
D36E/R293K 54.2 13.7 4.0 1.28 78.4 
R293S
a
 848.1 23.3 36.4 0.98 ∞ 
a: Zhang et al. 2009 
 
 
 
D36S had the Hill constant less than 1.0.  These results further confirmed that D36S lost its 
allosteric behaviour and H38S maintained this behaviour. 
Non-allosteric mutant D36S exhibited a Vmax value similar to that of WT, and its Km value 
was 43 % of WT.  It can be noted that D36S was saturated at a low substrate concentration and 
maintained a considerable catalytic efficiency.  Its overall catalytic activity (Vmax /Km) increased 
by 2.28-times from WT.  Meanwhile, the activity of D36S was inhibited at a high concentration 
of the Leu-Pro substrate, having a similar Ki value to WT.   
The allosteric mutant (H38S) had an appreciable Vmax (10 % of the WT‟s value) while 
showed a higher substrate affinity (Km: 1.3 mM) than WT (8.0 mM).  Also, no substrate 
inhibition was observed in H38S, as judged from its large Ki value (1162.5 mM).   
D36E/R293K was constructed to test an interaction between Asp
36
 and Arg
293
.  When the 
R293K mutation was introduced with the D36E mutation, the resultant double mutant kept the 
allosteric behaviour although it suffered a dramatically decrease in activity.  The lower Vmax 
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(3.1 %) and higher Km values (1.7-times) than those of WT indicated that the double mutant had 
a low catalytic efficiency and substrate affinity.   
5.2.3 Substrate Specificities  
In the presence of zinc or manganese as the catalytic metal ion, all Llaprol mutants 
exhibited similar substrate specificities to WT that they preferred hydrophobic amino acids at the 
N-terminus of Xaa-Pro dipeptides. Positively charged Arg-Pro and Lys-Pro were also hydrolyzed, 
whereas the hydrolysis of negatively charged Asp-Pro and Glu-Pro was not observed.  All 
mutants did not hydrolyze other peptides including Pro-Pro, Gly-Pro, Leu-Leu-Pro and Leu-Val-
Pro examined in this research.  The observed activities of Llaprol mutants toward different 
substrates were summarized in Table 5.2-2. 
Although WT and mutant Llaprols in this study hydrolyzed the five dipeptides listed in 
Table 5.2-2, they had different preference profiles toward these dipeptides.  Comparing with WT, 
the D36S mutant appeared to have higher specificities toward Lys-Pro.  In the presence of zinc, 
WT can hydrolyze Lys-Pro at a marginal rate (6.6 %) relative to the most preferred Leu-Pro 
dipeptides.  D36S can digest Lys-Pro at about a half rate of Leu-Pro.  Even in the presence of 
manganese, WT hydrolyzed Lys-Pro at 11.6 % of Leu-Pro, whereas D36S took Lys-Pro at the 
rate of 68.3 %.  It should also be noted that H38S retained its activity at significant levels toward 
Lys-Pro (70.6 %) and Arg-Pro (119.3 %) in the presence of zinc, comparing with those of WT 
(6.6 % to Lys-Pro; 12 % to Arg-Pro).  In the case of manganese, Lys-Pro hydrolysis by H38S 
reached 119.5 %, which exceeded that of WT (11.6 %).  Whereas D36S and H38S showed the 
changes in substrate specificities, the D36E/R293K mutant exhibited substrate specificities 
similar to WT in both metal ions, that is, it recognized Leu-Pro as its best substrates, (Table 5.2-
2).   
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Table 5.2-2  Activities of Llaprols for a variety of substrates  
 
Relative activity (Leu-Pro = 100%) 
 WT 
a
 D36S H38S D36E/R293K 
A) In 1mM zinc chloride 
Leu-Pro 100 ± 1.4 
(468.7 ± 6.6) 
100.0 ± 2.7 
(534.1 ± 14.5) 
100.0 ± 2.6 
(162.3 ± 4.2) 
100.0 ± 2.2 
(6.7 ± 0.14) 
Lys-Pro 6.6 ± 0.5 51.3 ± 4.5 70.6 ± 2.2 3.8 ± 0.8 
Phe-Pro 23.8 ± 0.4 44.2 ± 1.7 15.8 ± 3.9 5.3 ± 3.0 
Val-Pro 14.4 ± 0.4 28.8 ± 2.6 4.9 ± 1.4 16.3 ± 8.5 
Arg-Pro 12.0 ± 0.9 14.6 ± 2.3 119.3 ± 5.2 11.2 ± 3.5 
 
B) In 1 mM manganese chloride 
Leu-Pro 100.0 
(234.5 ± 6.3) 
100.0 ± 11.6 
(323.1 ± 37.5) 
100.0 ± 9.5 
(140.5 ± 13.4) 
100.0 
(14.7 ± 1.4) 
Lys-Pro 11.6 ± 2.1 68.3 ± 5.1 119.5 ± 7.0 10.9 ± 1.0 
Phe-Pro 70.8 ± 12.5 23.6 ± 3.3 24.8 ± 10.8 10.0 ± 0.6 
Val-Pro 68.1 ± 17.5 57.1 ± 2.9 12.6 ± 3.6 19.5 ± 5.4 
Arg-Pro 197.7 ± 5.6 25.9 ± 4.4 86.6 ± 9.7 16.7 ± 0.6 
Note: The number in parentheses indicates the specific activity (µmol/mg·min) toward Leu-Pro. 
a, Zhang et al. (2009) 
 
 
 
 
 
5.2.4 pH Dependency 
His
296
 acts as a proton acceptor in Llaprol reactions (Hu and Tanaka, 2009).  Thus the more 
deprotonated population of His
296
 exists, the higher activity of this enzyme should be shown.  
D36S showed a much higher activity (129.8 %) at pH 5.5 than WT (5.6 %) and other mutant 
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Llaprols (38.3% for D36E/R293K; 61.1 % for H38S), which was due to the disappearance of the 
negative charge of position 36. 
The data of pH dependency for each Llaprol mutants (D36S, H38S, D36E/R293K) are 
shown in Figure 5.2-2 (B, C, D), with WT Llaprol as a reference (Figure 5.2-2-A).  Each 
observed activity toward Leu-Pro at each pH was converted into the relative activity to that at pH 
6.5.  WT had a working pH range from 6.0 to 8.0.  Three mutants examined showed high 
activities between pH 6.0 and 7.0 as observed in WT, and they lost their activities at pH below 4 
and above 8.5.  The differences among these mutated and WT Llaprol were observed between 
pH 5.0 and 6.0.  At pH 5.0 and 5.5, WT showed little activities (0 and 5.6 %) for Leu-Pro (Figure 
5.2.2-A).  H38S (Figure 5.2.2-C) and D36E/R293K (Figure 5.2.2-D) showed considerable 
activities for Leu-Pro at pH 5.5 (61.1 % for H38S; 38.3 % for D36E/R293K).  Interestingly 
D36S (Figure 5.2.2-B) showed a sizable activity at pH 5.0 (40 %) and reached the highest 
activity at pH 5.5 (129.8 %).  These differences indicated the microenvironment in the active site 
cleft was changed by the disappearance of the charges of Asp
36
 or His
38
. 
5.2.5 Temperature Dependency 
Thermal dependency can reflect the local structural rigidity of the active site.  Figure 5.2-3-
A to D showed the temperature dependency of WT and mutated Llaprols.  All Llaprol mutants 
showed activities at similar working temperatures from 30 to 60 °C as observed in WT.  They 
were barely active at 20 °C and lost their activities at 70 °C.  The differences among the WT and 
mutated Llaprols in terms of the temperature dependency were observed at 60 °C.  Mutant D36S 
retained a high activity (120 %) at 60 °C (Figure 5.2-3-B), comparing with that of WT (80 %; 
Figure 5.2.3-A). In contrast, mutants H38S and D36E/R293K (Figure 5.2-3-C, D) showed the  
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Figure 5.2-2  pH dependency of WT and mutated Llaprol 
The reactions in this study were performed at assigned pHs (Temperature: 50 °C; Substrates: 2 
mM Leu-Pro; Metal ions:  1 mM ZnCl2).  The observed activity at each pH was plotted as 
relative activity to the activity at pH 6.5 for Leu-Pro. A) WT, B) D36S, C) H38S, D) 
D36E/R293K.  
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Figure 5.2-3  Thermal dependency of WT and mutated Llaprols 
The reactions in this study were performed at assigned temperatures (pH: 6.5; Substrates: 2 mM 
Leu-Pro; Metal ions:  1 mM ZnCl2). The observed activity at each temperature was plotted as 
relative activity to the activity at 50°C for Leu-Pro. A) WT B) D36S, C) H38S, D) D36E/R293K. 
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same profile as WT.  This suggested that Asp
36
 may influence the local structural stability of 
Llaprol. 
5.2.6 Denaturation Temperature 
By employing circular dichroism (CD) as a tool, denaturing temperatures were determined 
for D36S, H38S and D36E/R293K.  Plots between the temperature and dichroism ellipticity were 
shown in Figure 5.2-4.  These plots showed that the denaturation of secondary structures of 
Llaprol started at 50 °C, and completed at around 72 °C.  The denaturing temperatures of D36S, 
H38S, and D36E/R293K determined using Curve Expert 1.4 Program were 68, 67.1, and 67.9 °C,  
 
 
 
 
Figure 5.2-4  Thermal denaturation profile of mutated Llaprols. 
The plots for D36S are shown in squares; for H38S are show in circles; for D36E/R293K are 
shown in triangles.   
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respectively.  These results indicated the stability of the overall structures of these mutants were 
similar to that of WT Llaprol whose denaturing temperature is 67 °C (Yang and Tanaka, 2008).  
Thus, the mutations introduced by these Llaprol mutants did not affect overall structural stability, 
and their effects are limited to the local structures. 
5.3 Preliminary X-ray Crystallography of Llaprol 
5.3.1 WT Llaprol Crystallization from Commercially Kits 
When WT Llaprol was used for crystallization using Crystal Screen Kit 1 & 2, crystalloid 
particles of WT were observed in screening solution #18 of Kit 2.  Although crystalloid particles 
were also found in some other solutions in Kit 2, solution #18 allowed the formation of crystals.  
This solution contained 20 % (w/v) PEG8000, 0.1 M sodium cacodylate (pH 6.5), and 0.2 M 
magnesium acetate.  This condition was further optimized in following studies.   
5.3.2 Crystals Obtained Using Self-Made Screening Solutions 
Based on the observations in the section 5.3.1, screening conditions were optimized by 
varying the following factors: precipitant-PEG8000 concentration, pH of sodium cacodylate 
buffer, and different salts.  For this purpose, several series of screening solutions were prepared 
as shown in Appendix A.  Initially, series A to E were used for the WT crystallization.  Crystals 
of three types including a bipyramidal shape, a needle shape and stack of plates were observed in 
these series.  Due to the difficulty to manipulate the needle and plates shape crystals, this study 
focused on the bipyramidal crystals to apply them for X-ray diffraction studies.  Unfortunately, 
bipyramidal crystals of WT Llaprol grown under examined solutions were prone to crack.  At the 
stage of testing F series, loopless Llaprol-36-40 was used to crystallize in parallel with WT 
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Llaprol.  WT was crystallized in F series but the crystals are cracked as they grow (Figure 5.3-1-
A).  Interestingly, 36-40 was crystallized into a bipyramidal shape in the presence of 
magnesium acetate and a needle shape in the presence of manganese chloride, as shown in 
Figure 5.3-1-B, C.  Ultimately, the optimal conditions to crystallize the mutant 36-40 were 
determined as 10-12% (w/v) PEG8000/ 0.1 M magnesium acetate/ 0.1 M sodium cacodylate (pH 
6.5).  Bipyramidal crystals were formed with a reproducible manner under these conditions.  
5.3.3 The Effects of PEG8000 on the Crystal Growth of loopless Llaprol 36-40 
To further observe the crystal growth process of 36-40, different concentrations of 
PEG8000 (from 6 to 30% (w/v)) were employed in H series.  Results from this experiment were 
shown in Figure 5.3-2.  No crystal was formed at 6 and 8% (w/v) PEG8000 (Figure 5.3-2-A,B) 
because 36-40 was undersaturated (Figure 2.6-2).  When the concentration of PEG8000 
reached 10 and 12% (w/v), 36-40 was in a metastable zone, which was indicated by the well 
ordered crystals shown in Figure 5.3-2-C, D.  When the concentrations of PEG8000 further 
increased up to 30% (w/v), the smaller and cracked crystals formed, which indicated 36-40 
arrived at the nucleation zone. 
5.3.4 Preliminary X-ray Diffraction 
For crystals of loopless Llaprol 36-40 obtained in solution F17, the X-ray diffraction 
experiment was performed at SSSC.  The diffraction pattern was shown in Figure 5.3-1-D.  The 
crystals diffracted up to 4.6 Å but the space group could not be determined. 
To attain a better diffraction, a synchrotron X-ray diffraction analysis was employed for this 
study.  Glycerol and PEG8000 were tested with a flashing-freezing method to examine which is 
suitable to protect crystals under liquid nitrogen flashing.  It was observed mother liquors with an 
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Figure 5.3-1  Crystals obtained in this study and preliminary X-ray diffraction pattern. 
A: Cracked WT Llaprol crystal grown in 12% (w/v) PEG8000, 0.1M sodium cacodylate (pH 6.5), 
0.1M magnesium acetate; B: Needle shaped crystal of loopless Llaprol grown in 10% (w/v) 
PEG8000, 0.1M sodium cacodylate (pH 6.5), 0.1M manganese chloride; C: bipyramidal shaped 
crystal of loopless Llaprol grown in 12% (w/v) PEG8000, 0.1M sodium cacodylate (pH 6.5), 
0.1M magnesium acetate; D: X-ray diffraction pattern using a crystal shown in figure 5.3-1-C. 
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Figure 5.3-2  Effects of PEG8000 concentrations on the formation of crystals 
The crystals of 36-40 were set at room temperature using a hanging drop method. The mother 
liquor solutions in this set contained 0.1M sodium cacodylate (pH 6.5), 0.1 M magnesium acetate, 
and different concentration of PEG8000. The concentrations of PEG8000 from A to H are 6, 8, 
10, 12, 20, 22, 25, and 30% (w/v).   
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Figure 5.3-3  Cryocondition screening and X-ray diffraction in CLS.   
A, B, C: Crystals obtained in the presence of 2 , 4 and 6 % (v/v)  glycerol as the cyroprotectant; 
D: X-ray Diffraction pattern using a crystal shown in Figure 5.3-3-A in CLS. 
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addition of glycerol rather than PEG8000 could retain clear drops during the flashing-freezing 
experiment.  Thus, glycerol was used to protect the crystals for synchrotron X-ray diffraction.  
-40 was able to crystallize in an ordered form in the presence of low concentrations of 
glycerol with the optimized crystal growth solution aforementioned (Figure 5.3-3-A).  With the 
increase in the glycerol concentrations, the formation of ordered crystals became difficult as 
shown in Figure 5.3-3- B and C.  Crystals grown in the presence of 2% (v/v) glycerol were 
submitted to synchrotron X-ray diffraction and the result was shown in Figure 5.3-3-D.  The 
diffraction was still in insufficient qualities that only few diffracted spots were observed, which 
implied a deficient quality of the crystal. 
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6 DISCUSSIONS 
6.1 Contributions of Loop
32-43
 to the Activity 
6.1.1 Loop
32-43
 Protects the Active Site of Llaprol 
A loop structure is defined as a segment of a continuous polypeptide chain that forms a loop-
shaped structure without a regular secondary structure.  Loop structures are common structural 
components of proteins and on an average, five loops on each protein can be observed 
(Leszczynski and Rose, 1986).  One particular type of loops, named as “loop lids” or “flaps” can 
form a lid structure over an active site of proteins and can play essential roles in protein 
functions.  During catalysis, these loops can be apart from the active site to allow the 
introduction or release of substrates (open state); they can close over the active site to segregate 
the catalytic reaction from the environment (close state).  This type of loop structure has been 
observed in many enzymes as mentioned in section 2.5.   
A polypeptide segment (Gly
32
-Gly
43
) located between the 2 helix and 2 sheet of Llaprol 
forms a loop structure and its functional importance was examined in this study.  The computer 
model of Llaprol (Yang and Tanaka, 2008) based on a crystal structure of Pfprol shows that the 
Loop
32-43
 is projected over the active site located in the C-terminal domain of the other subunit, 
and each end of the Loop
32-43
 is a glycine residue.  Glycine residues have great freedom in terms 
of their conformations due to little steric hindrance of their hydrogen side chains.  This nature of 
glycine can provide the flexibility for adjacent residues.  For example, glycine has been shown to 
act as points of flexibility for hinge-type motions in the active-site loop of glutathione synthetase 
(Tanaka et al., 1993) and tryptophan synthase (Zhao and Somerville, 1993).  Moreover, regions 
containing Gly-X-X or X-X-Gly are suggested as flexible regions in proteins if either of two X 
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residues was Val, Leu, Ile, Ala, Ser, Thr and Asp (Yan and Sun, 1997).  The loop in Pfprol 
(Gly
33
-Thr-Ser-Pro-Leu-Gly-Gly-Gly
40
), which is corresponding to Loop
32-43
, shows its 
flexibility due to the existence of the glycine residues at the both ends of the loop (Maher et al. 
2004).  The amino acid sequence of Loop
32-43
 in Llaprol is Gly
32
-Leu-Ala-Ile-Asp-Pro-His-Glu-
Arg-Ile-Ala-Gly
43
, which has Gly-Leu-Ala and Ile-Ala-Gly at the base of the loop.  This property 
allows the flexibility of Loop
32-43
 in Llaprol.   
In addition, Loop
32-43 
on Llaprol is four residues longer than its corresponding loop in Pfprol.  
Coincidentally, there are four additional charged residues (Asp
36
, His
38
, Glu
39
 and Arg
40
, Figure 
2.4-3-B) in the middle of Llaprol Loop
32-43
, and no charged residue is found on the loop in Pfprol.  
Although Loop
32-43
in the Llaprol model was displayed in a tight space (Figure 2.4-3-A) which is 
calculated based on a short loop structure on Pfprol, the different length of the loops between 
Pfprol and Llaprol suggested that Llaprol Loop
32-43
 can be extended more and potentially had 
more conformational options than the loop
 
in Pfprol.   
Implications of the flexible feature of Loop
32-43
 were also obtained from crystallization 
studies of WT and -40 Llaprol.  During the crystallization of WT, cracked crystals were 
easily formed (Figure 5.3-1-A) either at 4 °C or room temperature while loopless mutant -40 
tended to form stable crystals (Figure 5.3-1-B, C).  Cracking of crystals observed in this study 
may be caused by the flexibility of the loop structure present in the protein crystal of WT.  The 
computer model of Llaprol shows that Loop
32-43
 is located at the interface between two subunits 
of Llaprol and projects down the active site cleft (Yang and Tanaka 2008).  The flexibility of this 
loop can affect the interaction between two subunits of Llaprol, even it may induce a large 
conformational shift.  When a central part of Loop
32-43
 was deleted in 36-40, the flexibility of 
the loop was limited by its length, which resulted in reducing this conformational shift.  Thus we 
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suspect that the cracking tendency of WT Llaprol provide another piece of evidence that the loop 
is flexible dynamically and prevents the formation of well-ordered crystals.   
Llaprol was inactivated when a central part (Asp
36
-Arg
40
) of Loop
32-43
 was knocked out 
(-40) or mutations were introduced at either Glu39 or Arg40 (E39S, R40S, R40K, R40E, 
D36S/E39S and H38S/R40S).  Both D36S and H38S mutants showed different substrate 
preferences and pH dependency of activity with WT, implying their influence on the substrate 
binding and the behaviour of the catalyst.  These results clearly indicate the importance of 
Loop
32-43
 in the catalytic efficiency of Llaprol.  Furthermore, the gel filtration testing on -40 
showed this mutant was a dimer as observed for WT, which suggests the deletion of the loop 
does not induce an overall change of quaternary structure but a local alteration.  For active 
mutants, D36S and H38S, CD experiments showed their thermal denaturing temperatures were 
not significantly changed, suggesting their overall secondary structures are similar to WT.  
Therefore, the introductions of mutations in Loop
32-43
 can cause local structural changes relevant 
to the enzyme activity, substrate binding and the microenviornment of catalytic residues.  This 
indicates that Loop
32-43
 is a crucial local structure for the enzyme activity of Llaprol, and it is 
likely through influencing the substrate binding and catalysis.   
The results and observations discussed above include 1) the location of Loop
32-43
 is situated 
between two protomers, 2) Loop
32-43
 influences interactions of the protomers, and 3) Loop
32-43 
is 
critical for substrate binding and catalytic efficiency.  These indicate Loop
32-43 
can be defined as 
a region that exhibits extensive rearrangements during the catalysis.  Although some loop 
structures are involved in catalytic processes without any direct interactions with active sites, as 
observed in the loop 6 in triose phosphate isomerase (TIM;Kempf et al., 2007), Llaprol Loop
32-43
 
is believed to affect catalysis through interactions with the active site and substrates.  During the 
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catalysis, Loop
32-43
 is most likely acting as an "active site flap" structure similar to that of 
aspartic proteinases.  It opens to allow substrate access to the active site cleft, closes on substrate 
binding and opens again to release products.  It is also able to stabilize the transition states.  To 
argue the behaviour of Loop
32-43 
clearly, some terms have to be defined before further discussion.  
In the absence of substrates or ligands, Llaprol Loop
32-43
 is believed to have both open and 
closed conformations.  As shown in Figure 6.1-1, at the open state, Loop
32-43
 situated apart from 
the active site cleft, which is in a flexible state (corresponding allosteric R state); whereas at the 
closed state, Loop
32-43
 extends over the active site (T state).  In the presence of substrates, 
Loop
32-43
 at the closed state can arrange proper interactions with a substrate and active site 
residues to initiate the catalytic cycle.  The motivation of triggering the maturation of the closed 
states will be discussed in section 6.1.2. 
6.1.2 The Closed Conformation of Loop
32-43
 
The results of this research proposed that the Loop
32-43
 plays functional roles through its 
motion between two major conformational states: open and close.  However, it is speculated that 
Loop
32-43
 has both states in a dynamic equilibrium in an apo enzyme form.  More populations 
take active closed conformation triggered by the ligand-binding in ligand-bound forms.  The 
dynamic nature of Loop
32-43
 over the active site begs the questions of how the residues on the 
loop contribute to conformational changes of the loop.   
Glu
39
 mutants (E39S and D36S/E39S) lost their activities, which imply essential roles of 
Glu
39 
in the enzyme activity.  Glu
39
 is adjacent to one positive charged residue Lys
108
 on the 
rigid body of N-terminal domain (Figure 6.1-2) which might be essential for maintaining the 
„open‟ conformation of the loop (Figure 6.1-1).  E39S or D36S/E39S eliminated this charge- 
charge interaction between Glu
39
 and Lys
108
so that Loop
32-43
 couldn‟t switch back to its „open‟ 
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Figure 6.1-1  Schematic view of motions of Loop
32-43
 in Llaprol. 
The C-terminal domain of subunit A and N-terminal of subunit B are coloured pink and light 
blue, respectively.  The triangle and pentagon are used to illustrate the S1 and S1 sites, 
respectively, which are located beside the zinc atoms (red spheres).  In the open state of Loop
32-43
, 
charge-charge interaction between Glu
39
 and Lys
108
 may be responsible for maintaining this 
position.  In the closed state of Loop
32-43
, Glu
39
 and Arg
40
 may be responsible for this position, 
where the S1 site is bound with the P1 residue (proline) and the charge-charge interaction 
between Asp
36
 and Arg
293 
would form the allosteric subsite.  The closed state brings His
38
 in the 
position to form the pseudo-S1' site that is responsible for the substrate inhibition.  
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Figure 6.1-2  Stereodiagram of Llaprol active site.  
Loop
32-43
 is shown in gray ribbon; negatively charged residues (Asp
36 
and Glu
39
) and positively 
charged residues (His
38
, Arg
40
 and Lys
108
) are shown in red and blue, respectively. In the active 
site cleft, zinc atoms are shown in gray spheres and the catalytic residue His
296
 is black. S1 site 
residues (His
292
, Tyr
329
, and Arg
337
) and S1 site residues (Phe
190
, Leu
193
, and Val
302
) are shown in 
cyan and yellow, respectively. Arg
293
, a key residue for the allostery and substrate inhibition of 
Llaprol, is shown in green. 
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state, which narrows down or even blocks substrates from the active site, resulting in no activity. 
Both R40S and H38S/R40S lost activity for Leu-Pro, indicating Arg
40
 is an important residue to 
keep the activity of Llaprol.  Judged from the molecular model of Llaprol, Arg
40
 may be in the 
hinge region of the lid.  I hypothesize that Arg
40
 may play a role in triggering Loop
32-43
 into a 
closed conformation, through charge-charge interaction with Glu
39
 (Figure 6.1-1) to transform 
Loop
32-43
 between open and closed conformations.  To test this hypothesis, R40K and R40E were 
constructed and studied.  Interestingly, no activity was observed in both mutants R40K and R40E, 
disproving the interaction between Arg
40
 and Glu
39
.  However, these results suggest that not only 
the charged property of Arg
40
 is important, but also its bulky property is necessary to maintain 
the activity of Llaprol.  Due to the inactivation of Arg
40
 mutants, the detailed mechanism has to 
be further investigated through X-ray crystallography. 
The inactivation by 36-40, E39S, R40S, R40K and R40E mutations observed in this study 
proves that the flexible Loop
32-43
, especially Glu
39
 and Arg
40
 on it, is required to maintain the 
activity of Llaprol.  In addition, the flexibility of Loop
32-43
 seems critical for the functionality of 
Llaprols.  In the following sections, the flexibility and important roles of this loop are further 
discussed in terms of allosteric behaviour and substrate inhibition.   
6.2 The Relationship of Asp
36
 and Arg
293
 to the Allosteric Behaviour of Llaprol 
Allostery is one of interesting properties of Llaprol and it is not reported in prolidases from 
other sources.  This study is the first attempt to solve the molecular mechanism of the allosteric 
behaviour observed in Llaprol. 
As discussed in section 6.1, Llaprol Loop
32-43
 is flexible over the active site and can act as a 
flap structure undergoing conformational changes during the catalytic cycle.  Allosteric 
regulation, being an essential part of the catalytic cycle, is likely attributed to the motions of the 
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flap Loop
32-43
.  A loop (from position-178 to 192; Loop
178-192
) in subunit of tryptophan 
synthase participates in the allosteric regulation (Ferrari et al., 2003).  This loop is highly 
flexible and can switch from an open to a closed state in response to ligand bindings.  Gly
181
 
located on Loop
178-192
 forms a hydrogen bond with Ser
178
 of subunit and this interaction is 
proved to be fundamental to transit allosteric signal between subunits (Spyrakis et al., 2006).  
Since Llaprol Loop
32-43
 is suggested to protect the catalytic environment similar to Loop
178-192
 
in tryptophan synthase, we expect interactions among Loop
32-43
 and residues in the active site 
cleft contribute to the allosteric signal transition. 
In this study, mutants D36S and D36E/R293K provide interesting results in terms of the 
allosteric behaviour of Llaprol.  When the negative charge of position 36 on the Loop
32-43
 was 
neutralized in D36S, mutant D36S showed 96% activity of WT and lost the allosteric behaviour 
with a Hill constant of 0.90 (Table 5.2-1), which suggested a negative charge at the position 36 
was necessary for maintaining the allosteric subsite of Llaprol.  Combined two observations 
that 1) positive charged Arg
293 
is a key residue for allostery (Zhang et al. 2009) and 2) Arg
293
 is 
close to Asp
36
, it is logical to conclude a charge-charge interaction between Asp
36
 and Arg
293
 
exists to form a substrate subsite for the allostery.  Double mutant D36E/R293K, mimicking the 
charge-charge interaction and keeping the distance of their  carbons, exhibited the allosteric 
behaviour, although it dramatically decreased the catalytic activity (Table 5.2-1).  Moreover, 
the thermal denaturing temperatures of D36S and D36E/R293K determined with CD did not 
show significant changes compared to WT, which indicates that the structure of these mutants 
likely fail in undergoing major structural changes.  Thus changes in observed behaviours are 
due to the mutations themselves.  These results provides the strong evidence to conclude the 
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significant roles of charge-charge interaction between Asp
36
 (the tip of the loop) and Arg
293
 
(beside the active site cleft) in the allosteric regulation.   
To generate allosteric behaviours, no matter how they are regulated, allosteric proteins must 
have at least a substrate binding subsite for the allostery.  The substrate binding subsite for the 
allostery (effector site) is normally located apart from the productive substrate binding site 
(active site).  Different subsites played diverse roles during the catalytic cycle of enzymes.  An 
effector site contributes to the allosteric regulation, whereas an active site provides a location 
for the catalytic reaction.  Moreover, the binding of an effector to the allosteric subsite can 
trigger the exposure of the active site for substrate binding, which activates the allosteric 
enzyme. 
In Llaprol, it is believed that the allosteric subsite is formed near the productive subsite 
because Asp
36
 and Arg
293 
(Figure 6.1-2) are located near the active site and influence the 
allosteric behaviour.  Negative carboxyl group (-COO
-
) of Asp
36
 and positive amine group (-
NH3
+
) of Arg
293
 likely play important roles in forming the allosteric subsite.  Results from the 
pH dependency and substrate specificity studies of D36S provided the evidence to support the 
above hypothesis.  D36S had a significantly high activity at pH 5.5 (Figure 5.2.4-1) in 
comparison to other mutated and WT Llaprols, suggesting the loss of a negative charge at 
position 36 has an impact on the microenvironment for catalyst-His
296 
(Hu and Tanaka, 2009).  
For catalysis, His
296
 has to stay deprotonated to accept proton from the intermediate of the 
enzyme reaction.  The more deprotonated population of His
296
 exists, the higher activity of this 
enzyme should be shown.  D36S showed a much higher activity (129.8 %) at pH 5.5 than WT 
(5.6 %) and other mutant Llaprols (38.3% for D36E/R293K; 61.1 % for H38S), which was due 
to the disappearance of the negative charge of position 36.  The removal of the negative charge 
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in D36S could indirectly increase the positive microenvironment of His
296
, because the absence 
of the negative charge of Asp
36
 left the positive charge of Arg
293
 near His
296
.  The extra positive 
charged groups around His
296
 in D36S allows a higher population of deprotonated His
296
 at 
lower pH.  Besides, D36S had a higher activity toward Lys-Pro than WT and D36E/R293K 
(Table 5.2-2).  The small side chain of serine at position 36 was more capable to allow the 
docking of dipeptides with a long side chain (i.e., Lys-Pro) than a bulky side chain (glutamic 
acid or aspartic acid) at position 36.  This indicated that Asp
36
 also limit the size of the 
productive substrate-binding pocket of WT when Asp
36
 formed an allsoteric subsite.  It is of 
interest that the non-allosteric D36S withstood a higher temperature than other Llaprols in this 
study (Figure 5.2-5).  This suggests that Asp
36
 influences the local structural stability of WT 
Llaprol.  In another words, the absence of the interaction between Asp
36
 and Arg
293 
results in 
local structural changes of the active site in the event of substrate binding.  Based on these 
analyses, we further conclud that the charge-charge interaction between Asp
36
 and Arg
293
 is 
most likely responsible for forming an allosteric binding subsite in Llaprol.   
Induced-fit model introduced in section 2.3.1 can fit well in explaining the allosteric 
behaviour of Llaprol.  When Leu-Pro as a substrate was introduced, the proline residue (P1‟ 
residue) in a substrate docked in the substrate binding site (S1‟ site), defined by His
292
, Tyr
329
, 
and Arg
337
.  Due to the flexible nature, Asp
36
 was able to interact with Arg
293
 forming an 
allosteric subsite when the loop takes the closed conformation.  The negative charge of Asp
36
 
would accommodate amine group of substrates (Xaa-Pro).  The binding of the amine group of 
Xaa-Pro to the allosteric site further induces a conformational change of Loop
32-43
 and the 
active site to expose the productive active site, which is discussed in next section.   
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6.3 Dual Roles of His
38
, a Substrate Binding Residue for Activity and Inhibition 
As mentioned in section 6.2, when the allosteric subsite is formed by Asp
36
 and Arg
293
 and 
is saturated with the effectors, the active site can be activated and bind to substrates for the 
catalysis.  His
38
, located at the tip of Loop
32-43
, is likely involved in the formation of the 
productive binding site for the catalysis in Llaprol, judged from following observations.  H38S 
had a significant decrease in its activity (10 % of WT), indicating the substitution of histidine to 
serine caused significant influence in the catalytic activity of Llaprol.  In addition, the substrate 
specificities of H38S compared to WT had significant increases for Arg-Pro and Lys-Pro, which 
reveals the contribution of His
38
 in the recognition of substrate.  His
38
 in WT likely had a larger 
influence than Asp
36
 on limiting the size of substrate, since D36S only changes behaviours in 
recognizing Lys-Pro.  The residue (Leu
37
) in Pfprol corresponding to this position (Figure 2.4-2-
B) is suggested as a substrate-binding site for P1 (Maher et al., 2004), which further supported 
that His
38
 of Llaprol was actually involved in forming the subsite for substrate binding.  
Combined with our previous study that Leu
193
, Phe
190
 and Val
302
 are confirmed as the S1 site 
residues in WT Llaprol (Hu and Tanaka, 2009), we believe His
38
 is another member of S1 site 
and moves along with conformational changes of Loop
32-43
.  Therefore, in WT, the saturation of 
allosteric subsites (defined with Asp
36
 and Arg
293
) with substrates Leu-Pro, incurs a 
conformational change of Loop
32-43
, which is expressed as a right position of His
38
 to form the 
intact S1 site with Leu
193
, Phe
190
 and Val
302 
at the active site cleft.  In this way, the P1 residue 
(e.g., Leu) and P1‟ residue (i.e., Pro) of the substrate can saturate the S1 site (His
38
, Leu
193
, Phe
190
, 
Val
302
) and S1‟ (His
292
, Tyr
329
 and Arg
337
) site, respectively.  Then, a metal bound hydroxyl 
group acts as the nucleophile to attack the peptide bound and deprotonated catalyst-His
296
 
immediately stabilize the intermediate product, as introduced in section 2.2.1. 
  
83 
As aforementioned, WT Llaprol showed the substrate inhibition.  This study demonstrated 
that H38S exhibited little substrate inhibition.  The Ki values for this mutant reached more than 
1000 mM (Table 5.2-1), implying His
38
 significantly influenced the substrate inhibition of 
Llaprol.  His
38
 is likely able to form a substrate binding subsite for inhibition, besides acting as a 
S1 site residue.  Zhang et al. (2009) considers Arg
293
 as a vital residue for the allostery and 
substrate inhibition because mutant R293S lost these two behaviours.  As discussed in the 
previous section, Arg
293
 can form an allosteric subsite with Asp
36
.  The H38S mutant of this 
study indicated that His
38
 can interact with Arg
293
 for the substrate inhibition, which supported 
our hypothesis that the allosteric behaviour and substrate inhibition in Llaprol were correlated 
with each other.  Phe
190
 is suggested as one of the key S1 site residues for the substrate binding.  
The alteration of Phe
190
 is found to be lethal to the enzyme activity (Hu and Tanaka, 2009).  This 
observation and the result acquired in this study (substrate inhibition of H38S) led us to suggest 
that S1 site residues-His
38
 and Phe
190
 associate with Arg
293 
to mimic the S1‟ site environment for 
binding proline through stacking forces between ring structures of His
38
 and Phe
190
.  When the 
substrates reached a higher concentration than the substrate molecules required for saturating the 
productive binding sites (S1 and S1‟), extra population of free substrates are able to dock their 
proline into the new inhibition subsite formed by His
38
, Phe
190
 and Arg
293
 (Figure 6.1-1), 
resulting in non-productive binding.  These bindings prevent the Loop
32-43
 from switching back 
to the open state, which results in inhibition of activity.  In this explanation of substrate 
inhibition, Llaprol takes advantages of Arg
293
 and S1 site residues (Phe
190
 and His
38
), mimicking 
the binding environment of S1
‟
 site (His
292
, Tyr
329
 and Arg
337
, shown in Figure 6.1-1) to form an 
inhibition subsite for binding the P1‟ residues (proline) of substrates, which resulted in the 
substrate inhibition.   
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6.4 General Conclusion 
To elucidate the contributions of residues on Loop
32-43
 to the functions of Llaprol, ten 
mutated prolidases were constructed and characterized on their substrate specificity, pH 
dependency, allosteric behaviour, thermal dependency and metal ion dependency.  The data were 
interpreted as follows. 
Combining the arguments in section 6.1, 6.2, and 6.3, it is concluded that Loop
32-43
 over the 
active site cleft is a key element in Llaprol to regulate and participate in the enzymatic reaction 
including allosteric activation, productive catalysis, and substrate inhibition.   Its flexible nature 
offered by Gly
32
 and Gly
43
 provides advantages to permit the central portion of Loop
32-43
 to 
communicate with the active site under certain circumstances.  The central portion of Loop
32-43
 
includes charged residues (Asp
36
, His
38
, Glu
39
 and Arg
40
), which are found to play specific roles 
at different stages of the catalysis. 
Disordered crystallization of WT and ordered manner of loopless mutant (36-40) imply 
that Loop
32-43
 influences the inter-subunit conformational states, and supports the hypothesis that 
the loop is a „lid‟ structure over the active site cleft.  Glu39 and Arg40 are important residues for 
enzyme activity and they may play roles in regulating the open and closed conformation of 
Loop
32-43
.  Asp
36
 interacting with Arg
293
 through charge-charge attractions, contributes to the 
allosteric subsite formation and the interaction is likely the critical component of the allosteric 
site of Llaprol.  His
38
 is a residue involved in forming substrate subsite for inhibition and it can 
recognize the substrates.   
In a summary, Loop
32-43
 is flexible and it has open and closed conformations.  This nature, 
relying on the existence of Glu
39
, Arg
40
 and possibly Lys
108 
(Figure 6.1-2), is important to 
maintain the activity of Llaprol.  When the loop takes the closed conformation, the tip of the loop 
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(Asp
36
 and His
38
) can extend over the active site pocket and be involved in the catalysis of 
Llaprol.  Asp
36
 interacting with Arg
293
 forms an allosteric subsite, allowing the bound of the N-
terminus amine group of the substrates (Xaa-Pro).  The saturation of the allosteric site with 
substrates further allows the communications of His
38
 with other substrate binding residues to 
form an intact active site (S1 site for Xaa residue).  When the substrate concentrations increase, 
His
38
, Phe
190
 and Arg
293
 mimic the microenvironment of S1‟ site and bind to the ring structure of 
proline residue in the substrates.  The non-productive binding site is formed to block the 
appropriate binding for catalysis, which results in the substrate inhibition.  Since Glu
39
 and Arg
40
 
mutants are inactivated, the dynamic change and their specific roles during catalysis are still 
ambiguous.  A model based on a real structure is really necessary.  Further X-ray crystallization 
studies on Llaprol for additional evidences are being conducted. 
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7 FUTURE RESEARCH 
This thesis research provides a platform to understand the mechanism of allosteric 
behaviour and substrate inhibition, whose mechanisms are still elusive.  The molecular 
mechanisms of these interesting behaviours in Llaprol can be further studied at the atomic level 
with X-ray crystallography.  Although several crystal structures of prolidase from different 
sources (such as Pyrococcus bacteria and Homo sapiens) are solved, the crystal structures in the 
presence of their substrate or analogues are scarce.  These native structures of prolidase are not 
able to provide solid evidence in the substrate binding sites and catalytic mechanism.  To prove 
the substrate binding subsites for allostery, catalysis, and substrate inhibition of Llaprol, crystal 
structures of both native Llaprol and its complex with substrate analogues, products and 
intermediate analogues, have to be solved at high resolutions (at least 2.0 Å).  The interpretation 
from these structures would be able to provide more dynamic pictures of Llaprol and how these 
changes are related to its function. 
In this thesis study, the crystallization conditions of Llaprol were successfully obtained, 
although the preliminary X-ray diffraction failed in generating sufficient data for the structure 
determination.  Based on our knowledge, the bottleneck for this problem is obtaining well-
ordered crystals.  Crystal growth conditions have to be further optimized in order to obtain better 
diffractions for interpreting the protein structure of Llaprol.  Besides, for solving the complex 
structure of Llaprol and its analogues, analogues have to be designed and synthesized. 
When the crystal structure is successfully solved, its information shall be valuable to 
elucidate the mechanism of substrate specificity, allostery and substrate inhibition in Llaprol.  
This knowledge can further guide our practical manipulation of Llaprol to reduce the substrate 
inhibition and allostery, moreover to increase the substrate conversion as well as to broad the 
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substrate specificity, aiming to the applications in debittering process of cheese-making and 
treating prolidase deficiency patients as well as the never gas detoxification.  
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APPENDIX A 
Series of Self-Made Crystallization Screening Solutions  
 
Tube # Recipe 
A1 18% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M ZnAcetate 
A2 18% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
A3 18% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2 
A4 18% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CoNO3 
A5 18% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
A6 20% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M ZnAcetate 
A7 20% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
A8 20% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2 
A9 20% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CoNO3 
A10 20% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
A11 22% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M ZnAcetate 
A12 22% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
A13 22% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2 
A14 22% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CoNO3 
A15 22% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
B1 36% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M ZnAcetate 
B2 36% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
B3 36% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2 
B4 36% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M CoNO3 
B5 36% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
B6 42% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M ZnAcetate 
B7 42% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
B8 42% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2 
B9 42% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M CoNO3 
B10 42% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
B11 48% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M ZnAcetate 
B12 48% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
B13 48% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2 
B14 48% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M CoNO3 
B15 48% PEG3350, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
C1 18% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M CaAcetate 
C2 18% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M MgAcetate 
C3 20% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M CaAcetate 
C4 20% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M MgAcetate 
C5 22% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M CaAcetate 
C6 22% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M MgAcetate 
C7 18% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M CaAcetate 
C8 18% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M MgAcetate 
C9 20% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M CaAcetate 
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C10 20% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M MgAcetate 
C11 22% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M CaAcetate 
C12 22% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M MgAcetate 
C13 18% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M CaAcetate, 5% iProOH 
C14 18% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M MgAcetate, 5% iProOH 
C15 20% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M CaAcetate, 5% iProOH 
C16 20% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M MgAcetate, 5% iProOH 
C17 22% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M CaAcetate, 5% iProOH 
C18 22% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M MgAcetate, 5% iProOH 
C19 18% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M CaAcetate, 5% iProOH 
C20 18% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M MgAcetate, 5% iProOH 
C21 20% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M CaAcetate, 5% iProOH 
C22 20% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M MgAcetate, 5% iProOH 
C23 22% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M CaAcetate, 5% iProOH 
C24 22% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M MgAcetate, 5% iProOH 
D1 18% PEG8000, 0.1M Na Citrate (pH 6.0), 0.1M CaAcetate 
D2 18% PEG8000, 0.1M Na Citrate (pH 6.0), 0.1M MgAcetate 
D3 20% PEG8000, 0.1M Na Citrate (pH 6.0), 0.1M CaAcetate 
D4 20% PEG8000, 0.1M Na Citrate (pH 6.0), 0.1M MgAcetate 
D5 22% PEG8000, 0.1M Na Citrate (pH 6.0), 0.1M CaAcetate 
D6 22% PEG8000, 0.1M Na Citrate (pH 6.0), 0.1M MgAcetate 
D7 18% PEG8000, 0.1M Na Citrate (pH 6.5), 0.1M CaAcetate 
D8 18% PEG8000, 0.1M Na Citrate (pH 6.5), 0.1M MgAcetate 
D9 20% PEG8000, 0.1M Na Citrate (pH 6.5), 0.1M CaAcetate 
D10 20% PEG8000, 0.1M Na Citrate (pH 6.5), 0.1M MgAcetate 
D11 22% PEG8000, 0.1M Na Citrate (pH 6.5), 0.1M CaAcetate 
D12 22% PEG8000, 0.1M Na Citrate (pH 6.5), 0.1M MgAcetate 
D13 18% PEG8000, 0.1M MOPS (pH 6.5), 0.1M CaAcetate 
D14 18% PEG8000, 0.1M MOPS (pH 6.5), 0.1M MgAcetate 
D15 20% PEG8000, 0.1M MOPS (pH 6.5), 0.1M CaAcetate 
D16 20% PEG8000, 0.1M MOPS (pH 6.5), 0.1M MgAcetate 
D17 22% PEG8000, 0.1M MOPS (pH 6.5), 0.1M CaAcetate 
D18 22% PEG8000, 0.1M MOPS (pH 6.5), 0.1M MgAcetate 
D19 18% PEG8000, 0.1M MES (pH 6.5), 0.1M CaAcetate 
D20 18% PEG8000, 0.1M MES (pH 6.5), 0.1M MgAcetate 
D21 20% PEG8000, 0.1M MES (pH 6.5), 0.1M CaAcetate 
D22 20% PEG8000, 0.1M MES (pH 6.5), 0.1M MgAcetate 
D23 22% PEG8000, 0.1M MES (pH 6.5), 0.1M CaAcetate 
D24 22% PEG8000, 0.1M MES (pH 6.5), 0.1M MgAcetate 
E1 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
E2 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 10mM Leu 
E3 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 10mM Pro 
E4 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT 
E5 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT, 10 mM Pro 
E6 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT, 10 mM Pro, 
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10mM Leu 
E7 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
E8 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 10 mM Leu 
E9 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 10 mM Pro 
E10 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1 mM DTT 
E11 14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1 mM DTT, 10 mM Pro 
E12 
14% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1 mM DTT, 10 mM Pro, 
10 mM Leu 
E13 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
E14 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 10 mM Leu 
E15 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 10 mM Pro 
E16 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT 
E17 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT, 10 mM Pro 
E18 
16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT, 10 mM Pro, 
10 mM Leu 
E19 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
E20 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 10 mM Leu 
E21 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 10 mM Pro 
E22 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1 mM DTT 
E23 16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1 mM DTT, 10 mM Pro 
E24 
16% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1 mM DTT, 10 mM Pro, 
10 mM Leu 
F1 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
F2 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 10 mM Leu 
F3 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT 
F4 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT, 10mM Leu 
F5 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
F6 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 10 mM Leu 
F7 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1 mM DTT 
F8 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M mgAcetate, 1 mM DTT, 10 mM Leu 
F9 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2 
F10 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2, 10 mM Leu 
F11 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2, 1 mM DTT 
F12 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2, 1 mM DTT, 10mM Leu 
F13 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
F14 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 10 mM Leu 
F15 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT 
F16 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate, 1 mM DTT, 10 mM Leu 
F17 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
F18 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 10 mM Leu 
F19 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1 mM DTT 
F20 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M mgAcetate, 1 mM DTT, 10 mM Leu 
F21 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2 
F22 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2, 10 mM Leu 
F23 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2, 1 mM DTT 
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F24 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2, 1 mM DTT, 10 mM Leu 
G1 12% PEG8000, 0.1M NaCacodylate (pH 5.5), 0.1M CaAcetate 
G2 12% PEG8000, 0.1M NaCacodylate (pH 5.5), 0.1M MgAcetate 
G3 12% PEG8000, 0.1M NaCacodylate (pH 5.5), 0.1M MnCl2 
G4 12% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M CaAcetate 
G5 12% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M MgAcetate 
G6 12% PEG8000, 0.1M NaCacodylate (pH 6.0), 0.1M MnCl2 
G7 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M CaAcetate 
G8 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
G9 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MnCl2 
G10 12% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M CaAcetate 
G11 12% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M MgAcetate 
G12 12% PEG8000, 0.1M NaCacodylate (pH 7.0), 0.1M MnCl2 
H1 6% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
H2 8% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
H3 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
H4 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
H5 20% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
H6 22% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
H7 25% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
H8 30% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
I1 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate 
I2 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 5% glycerol 
I3 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 10% glycerol 
I4 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 15% glycerol 
I5 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 20% glycerol 
I6 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 25% glycerol 
I7 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 30% glycerol 
I8 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 35% glycerol 
I9 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 50% glycerol 
J1 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1% glycerol 
J2 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 2% glycerol 
J3 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 3% glycerol 
J4 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 4% glycerol 
J5 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 5% glycerol 
J6 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 6% glycerol 
J7 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 7% glycerol 
J8 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 8% glycerol 
J9 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 9% glycerol 
J10 10% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 10% glycerol 
J11 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 1% glycerol 
J12 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 2% glycerol 
J13 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 3% glycerol 
J14 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 4% glycerol 
J15 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 5% glycerol 
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J16 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 6% glycerol 
J17 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 7% glycerol 
J18 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 8% glycerol 
J19 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 9% glycerol 
J20 12% PEG8000, 0.1M NaCacodylate (pH 6.5), 0.1M MgAcetate, 10% glycerol 
 
Note: Percentage for PEG8000 and glycerol are expressed as weight per volume and volume per 
volume, respectively.   
 
